

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/82, A01H 5/00	A1	(11) International Publication Number: WO 95/20668 (43) International Publication Date: 3 August 1995 (03.08.95)
(21) International Application Number: PCT/GB95/00188 (22) International Filing Date: 31 January 1995 (31.01.95) (30) Priority Data: 9401780.3 31 January 1994 (31.01.94) GB (71) Applicants (for all designated States except US): NICKERSON BIOCEM LIMITED [GB/GB]; Cambridge Science Park, Milton Road, Cambridge CB4 4GZ (GB). GENE SHEARS PTY. LIMITED [AU/AU]; Level 2, 154 Pacific Highway, St. Leonards, NSW (AU). (72) Inventors; and (75) Inventors/Applicants (for US only): PAUL, Wyatt [GB/GB]; Flat 5, 34 Stoughton Road, Leicester, Leicestershire LE2 2EB (GB). SCOTT, Roderick, John [GB/GB]; 101 Holmfield Road, Leicester, Leicestershire (GB). BETZNER, Andreas [DE/AU]; 11 Archer Street, Dickson, ACT 2602 (AU). HUTTNER, Eric [FR/AU]; 3 Barada Crescent, Aranda, ACT 2614 (AU). LENEÉ, Phillipe [FR/FR]; 12, rue des Roches, F-63110 Beaumont (FR). PEREZ, Pascual [FR/FR]; 21, allée du Parc, F-63110 Beaumont (FR). (74) Agents: CHAPMAN, Paul, William et al.; Kilburn & Strode, 30 John Street, London WC1N 2DD (GB).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). Published With international search report.
(54) Title: METHODS FOR THE PRODUCTION OF MODIFIED PLANTS		
(57) Abstract Methods for the production of modified plants are provided. In these methods a first line and a second line are crossed to produce a plant having a phenotypic trait, wherein neither the first or second lines possess the phenotypic trait, and wherein at least one of the parent lines is transgenic. Plants produced by the methods of the invention are also described.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

METHODS FOR THE PRODUCTION OF MODIFIED PLANTS

This invention relates to the production of plants having one or more desired phenotypic traits. In particular embodiments, the phenotypic trait is male sterility, and so the invention relates in those embodiments to male sterile plants, which are useful in hybrid seed production, and to the production of such plants.

Various routes for high level expression of foreign genes in plant cells have been explored over the years. Increasing levels of transcription using strong promoters have been obtained; promoters available include DNA virus promoters (such as p35S from CaMV; Fang *et al*, *The Plant Cell* 1 141-150 (1989)), plant gene promoters (such as EFE1 α ; Curie *et al*, *Plant Molecular Biology* 18 183-1089 (1992)) and bacterial promoters (such as pMAS; Fox *et al*, *Plant Molecular Biology* 20 219-233 (1992)). These promoters give high level of transcription and expression in many tissues (including leaves, stems, roots, flowers and seeds) of the plant. They are sometimes called constitutive promoters. Other promoters confer better expression in particular tissues (for example, the MAS promoter transcribes genes more efficiently in wounded tissues).

For certain applications, the expression of a gene is desired only in particular tissues or at a particular period of the plant development; for example to increase the level of expression of a heterologous protein, it is useful to express the gene specifically in seeds, as seeds are the principal organ for protein storage in plants. Expression of genes in certain tissues or organs of the plant or at a precise stage of plant development generally requires tissue-specific promoters. Seed-specific promoters have been characterised (for example, the promoter of the β -conglycine gene: Chen *et al*, *The EMBO Journal* 7 297-302 (1988) and Calgene's EP-A-0255378), as have root-specific promoters (such as the *Agrobacterium tumefaciens* roll promoter: Leach and Aoyagi *Plant Science* 79 69-76 (1991)).

Seed-specific promoters have been used to express pharmaceutical proteins in plant seeds (Vandekerckhove *et al*, *Bio/Technology* 7 929-932 (1989)). Stable expression of a gene under the control of seed-specific promoters has been obtained, and heterologous proteins were expressed, only in seeds, at a high expression level. Plants recovered from those seeds expressed the gene in their seeds, and the phenotype was transmitted from progeny to progeny.

In the production of industrially or pharmaceutically useful proteins, or other heterologous proteins, under the control of constitutive or seed-specific promoters in plants, F1 seeds will be sold to farmers to grow the plants and to produce seeds which will contain the protein of interest. In this system of production, the F1 line which expresses the gene of interest is grown by farmers and can be multiplied or reproduced by growers themselves or by competitors. Moreover, if the plant breeding industry should become required by law to control the distribution of all seeds sold, the fact that the above production process does not prevent the dissemination of genetically modified plants becomes a very significant issue.

From the above, it is apparent that there is a need for hybrid plants which

- (i) have a desired phenotypic trait as a result of the expression of a certain gene (or suite of genes), and
- (ii) are the result of a cross between two parents, neither of which have, either at all or to a substantial degree, the phenotypic trait in question.

However, the provision of such plants is not the whole extent of the problem, as there are some phenotypic traits which result from the *non-expression* of a gene (or suite of genes. One trait which may be (but is not necessarily) the result of

non-expression of a gene is male sterility.

Hybrid seed production involves the cross of two different plants. Because most crops are able to self-pollinate, the female parent in the cross must be prevented from self-pollinating ("selfing") so that it will yield 100% of hybrid seeds. This has been achieved in several different ways:

- (a) by mechanically removing or chemically inactivating the pollen-producing organs of the female parent before they reach maturity; this method has been used for example in maize (corn) and tomato;
- (b) by using cytoplasmic male sterile (CMS) mutant plants; this method has been used for example in oilseed rape and sunflower;
- (c) by using a recessive nuclear male sterile mutant plant; and
- (d) by using a dominant nuclear male sterile genetically engineered plant (artificial male sterility or AMS) as described for example in Mariani *et al*, *Nature* 347 737-741 (1990) or in Worrall *et al*, *The Plant Cell* 4 759-771 (1992).

There are practical difficulties with each of the above. Mechanical male sterilisation ((a) above) is easy and flexible. But it is labour intensive, costly and also prone to human error, giving a problem of quality of hybrid seeds batches.

It is practical only for species where the flower is big enough to be emasculated manually; it is not practical, for example, for most cereals. An attempt to overcome this difficulty and reduce costs is by using chemical instead of mechanical emasculation. The efficiency of this technique is very dependent on environment conditions at the time of spraying the gametocide, and leads the seed

producer to take a considerable risk each season. The cost of the gametocide and the spraying is also significant.

5 Cytoplasmic male sterility ((b) above) is very convenient, and allow easy maintenance of the female line. But its use is limited by availability of the appropriate mutant plant in each species of interest. The loss of cytoplasmic genetic diversity when all breeders use the same cytoplasm in their breeding program can be a serious problem as seen in the US on maize in the 1970s. And the maintenance of sterility relies on the existence of a maintaining cytoplasm.

10 Recessive nuclear male sterility ((c) above) is not practical. Because the male sterility gene is recessive, maintenance of the male sterile line involves screening the 1/4 of male sterile plants out of 3/4 fertile in the selfed progeny of an heterozygous plants. In the absence of a tightly linked selectable or easily screenable marker this is practically impossible. This is the problem that artificial male sterility has tried to solve.

15 Artificial male sterility ((d) above) has solved the problems of the other systems but only to some extent. The AMS gene system is potentially universal, being limited only to genetically transformable species. It does not rely on the existence of a mutant as in CMS. The maintenance of the male sterile line is obtained by engineering a dominant male sterility gene linked to a marker gene that allows selection of AMS plants in a population segregating 1/2 AMS plants. To be practical, this marker is often a herbicide resistance gene. But this process is
25 undesirable for several reasons:

- Agronomy: the seed production can be affected by the need to eliminate half the female plants (the fertile segregants) from the field. The result is a heterogenous plant density, and potentially lower yield and lower quality

of the seeds. The cost of spraying the herbicide is significant.

- Use of the herbicide: on some crops, such as vegetables, the use of a herbicide resistance gene, and the subsequent use by farmers of the herbicide is not desirable. Generally speaking, there is a tendency to restrict the use of herbicide as much as possible.
- The female line can be stolen easily. Once sold on distant and not easily controllable markets, the basic seeds can be multiplied by the local seed producer without the breeder's knowledge, control or share of the profit.

Disadvantages with a conventional AMS system can be appreciated by looking at a particular example. The AMS system which is the subject of EP-A-0344029 (Plant Genetic Systems (PGS)) is based on the tissue-specific expression of a toxin gene (Ribonuclease, "Barnase") to generate the male-sterile parent for hybrid seed production. The genetic linkage of the toxin to a selection marker (herbicide resistance) provides the basis for the selection of male-sterile plants. Fertility can be restored during hybrid seed production by crossing with a male-fertile parent (restorer line) that expresses a toxin inhibitor ("Barstar").

The problem with the PGS system lies in the production of the male-sterile line, which is used as the female parent in hybrid seed production. Due to the dominant character of the toxin, the female parent has to be propagated by crossing the heterozygous line (-/+) with a male fertile line (+/+). As the toxin gene segregates, only half of the progenies (male-sterile and herbicide resistant) from this cross can be used for hybrid seed production; the other half (male-fertile and herbicide sensitive) has to be eliminated and is therefore lost for hybrid seed production.

It is the post-germination selection of male-sterile plants that the seed producer seeks to avoid for three reasons:

1. The production of the female parent is inefficient (50% loss).
2. The post-germinal selection in the field might cause heterogeneity in plant distribution in the field, which could negatively affect seed yield. Computer simulations revealed patches with a high number of plants and patches that are almost void of plants. Attempts to mitigate this problem using agricultural practices, such as planting at higher density or going through the field with machinery more often, mean extra costs for the seed producer.
3. The use of a herbicide resistance selection marker could increase the difficulty in obtaining permission to release the crop and market the product, especially for vegetables.

The maintenance problem of a dominant AMS gene has to some extent been addressed. First, a solution was proposed which involved making the AMS gene inducible (WO-A-9008830 (ICI)). In the absence of the inducer, the plant is fertile and can therefore be multiplied easily. Spraying with an inducer turns the AMS gene on and causes the plant to be sterile. This approach is widely believed to be not practical because of its sensitivity to environmental conditions at the time of spraying the inducer. The risk to the seed producer if the inducer fails to perform is enormous. This is basically no improvement on the use of gametocides.

Secondly, a proposal to solve the same problem of maintaining the female line (WO-A-9201799 (Paladin Hybrids)) describes the use of a cross to generate the female line, but relies on an inducible or conditional male sterility in the plant used

as a female to perform that cross. It does not describe a workable system, only a limited set of genes which are not shown in the application to work practically.

5 In summary, AMS is the most satisfactory available male sterility system at the moment, but it does not provide a generally acceptable method for producing the female parent. The method involves some undesirable technology and costs, and does not protect the valuable female variety from being illegally copied. So it seems that a lot of work has been done to improve the efficiency of hybrid seeds production. Nevertheless, in order to produce hybrid seeds economically, there is still the need for a system which would associate the advantages of the above mentioned systems and overcome their limitation. In particular, the advantage of CMS in terms of maintenance and protection of the female line would be very useful in conjunction with a potentially universal system based on AMS.

10
15 More recently, there has been disclosed (EP-A-0589841 (CIBA-GEIGY)) a method of producing plants which are made sterile, the method comprising:

20 (a) transforming a first parent plant cell with a first expression cassette, the cassette comprising a nucleotide sequence encoding an anther-specific 5' regulatory region operably linked to a nucleotide sequence which encodes a transactivator polypeptide;

(b) regenerating a transformed plant, Parent 1, from said first transformed plant cell;

25 (c) transforming a second parent plant cell with a second expression cassette comprising a target nucleotide sequence which is capable of being activated by said transactivator polypeptide operably linked to a nucleotide sequence which encodes antisense RNA or a polypeptide capable of

disrupting the formation of visible pollen;

(d) regenerating a transformed plant, Parent 2, from said second transformed plant cell; and

5

(e) crossing Parent 1 with Parent 2 to obtain male-sterile offspring.

This document may represent prior art in certain states under certain circumstances.

10

It has now been found that it is possible by means of binary systems to solve or at least mitigate the problems discussed above.

15

According to a first aspect of the invention, there is provided a method for producing a plant having a desired phenotypic trait, the method comprising crossing a first line with a second line wherein each of the first and second lines lack the phenotypic trait in question and wherein at least one of the first and second lines is transgenic, with the proviso that when the desired phenotypic trait is male sterility this does not result from the action of a transactivator polypeptide on a target nucleotide sequence.

20

25

The term "transgenic", in the context of this invention, should not be taken to be limited to referring to plants containing in their germ line one or more genes from another species (plant or otherwise), although transgenic plants may contain such a gene or genes. Rather, the term refers more broadly to any plant whose germ line has been the subject of technical intervention by recombinant DNA technology. So, for example, a plant in whose germ line an endogenous gene has been deleted, duplicated, activated or modified is a transgenic plant for the purposes of this invention as much as a plant to whose germ line an exogenous DNA sequence has been added.

30

In certain important embodiments of the invention, the phenotypic trait is (generally artificial) male sterility. In other important embodiments, the phenotypic trait may be the production of a heterologous protein either specifically in the seed or elsewhere in the plant.

5

Preferably, both the first and second lines are transgenic.

The cross between the first and second lines will usually be achieved in a manner which avoids self-pollination. At least for the male sterility embodiments of the invention, because of the small scale on which it has to be performed, the non-self-pollinating cross can make use of processes which would be unacceptable for large scale commercial hybrid seeds production, like chemical emasculation for cereals. It can also be more thoroughly controlled for quality than a non-self-pollinating cross performed for commercial hybrid seeds production. The scale of a non-self-pollinating cross operation associated with the present invention will be much smaller than the current hybrid production surface since this process will be used at the basic seed's (hybrid parent) production level only; a multiplication factor of 200 (a conservative estimate for maize), for example, means that for producing hybrid seeds needed to plant 40,000 surface units of hybrid maize, only one surface unit has to be manually detasseled (say) as opposed to 200 in the present process. In the case of tomato, because the seed production process takes place in glasshouses, production of a male sterile female in accordance with the invention may involve manual emasculation of the first line and pollination with pollen from the second line, in a process similar to the one currently used to produce hybrid seeds. The scale however will be very much reduced (perhaps a thousand fold).

In relation to male sterility, the use of sufficiently fertile plants as parents of the female line distinguishes the present invention from the cryptocytotoxic AMS proposed, but not completely described, in WO-A-9201799 (Paladin Hybrids). Each of the two parents of the female line contains in the homozygous condition

30

a gene which has no effect by itself. Combination of the two genes in the same plant, as obtained in the progeny of a cross between the two parents, create male sterility.

5 It is not critical that plants of the first and second lines (which in the description of preferred embodiments of the invention may be referred to as Line A and Line B, respectively) be fully fertile (or otherwise lacking the phenotypic trait sought in the hybrid progeny). In relation to fertility, it is important that they be capable of being selfed, and that in the homozygous condition they be fertile enough to be
10 multiplied at acceptable or reasonable cost. Plants of the first and second lines can be isogenic, or different in the case of a three way hybrid. The fertility of the final product (the hybrid seed) is not always critical. For some outcrossing species (eg maize), the hybrid need not be 100% fertile. In other cases (eg tomato), in relation to male sterility embodiments of the invention, the hybrid needs to be fully
15 fertile; a restorer gene able to restore male sterility is used.

There are a number of different ways in which the invention can be implemented. In certain embodiments of the invention, the first and second lines have the following characteristics:

20

- (a) the first line comprises homologous or heterologous DNA which controls the desired phenotypic trait and in the first line is adapted such that the line does not have the phenotypic trait, and
- 25 (b) the second line has DNA which when present in the same plant as the phenotypic trait control DNA adapts the phenotypic trait control DNA to give rise to the phenotypic trait (this may be called a sterility adapter DNA).

30

The phenotypic trait control DNA may be male fertility or sterility control DNA.

5 In this way, a gene in one of the first and second lines is capable of causing absolute male sterility (or another desired phenotypic trait) in the presence of a gene in the other of the first and second lines, both genes being present in the heterozygous condition of the hybrid progeny, which then forms the female parent in the cross to produce commercial hybrid seeds.

10 The male sterility control sequence in the first line may comprise a sequence which, when expressed, confers male fertility on the plant. In these circumstances, the male sterility control sequence is expressed in the first line, which is therefore phenotypically normal (at least in respect of male sterility). The sterility adapter DNA of the second line would then act to prevent (at least partially) expression of the sterility control sequence in a hybrid. These embodiments of the invention may be said to involve inactivation of an "active" artificial male sterility gene.

15

For example, the first line may comprise

- 20 (i) two genes, designated *ms* and *ms**, respectively, expression of at least one of which is needed for male fertility and
- (ii) a prevention or disruption sequence (such as DNA encoding a ribozyme, designated *R_{ms}*, or DNA encoding antisense RNA, designated *A_{ms}*, specific for *ms*) which prevents or disrupts the proper expression of the *ms* gene.

25

This line will be male fertile, by virtue of the expression of *ms**, which is not disrupted by the ribozyme *R_{ms}* or the antisense *A_{ms}*. The second line will in these circumstances comprise

- 30 (i) the two genes, designated *ms* and *ms**, respectively, expression of at least one of which is needed for male fertility and

- (ii) a prevention or disruption sequence (such as DNA encoding a ribozyme, designated R_{ms^*} , or DNA encoding antisense RNA, designated A_{ms^*} , specific for ms^*) which prevents or disrupts the proper expression of the ms^* gene.

5

This line, too, will be male fertile, by virtue of the expression of ms , which is not disrupted by the ribozyme R_{ms^*} or the antisense A_{ms^*} . When the two lines are crossed, the resulting plant will be male sterile, as the proper expression both the ms and the ms^* genes is disrupted. Male fertility may be restored by the expression of a third male fertility gene ms^{**} which is resistant to both ribozymes R_{ms} and R_{ms^*} (or the corresponding antisense or other disruptors).

10

This embodiment of the invention is not limited to the use of ribozymes and antisense. Any DNA which directly or indirectly disrupts or prevents, in a sufficiently specific manner, the proper expression of the appropriate male fertility gene (ms or ms^*) can be used. Examples of male fertility genes ms or ms^* include *ms2-C103* (Aarts *et al*, *Nature*, 363: 715-717 (1993)), *APRT* (Moffatt *et al*, *Plant Molecular Biology*, 18: 653-662 (1992)) and any other suitable natural or artificial male fertility-controlling gene, which may for example be identified by mutation studies. The designation " ms " or " ms^* " is not intended to be limited to any particular gene, whether natural or artificial.

15

20

Parenthetically, it should be noted that in this application, unless the context requires otherwise, the use of the word "gene" simply denotes a transcribable or expressible DNA sequence and is not limited to mean an exact replica of an expressible genomic DNA sequence (although that may be preferred in certain circumstances); it is to be understood, therefore that synthetic DNAs, cDNAs and "minigenes", which contain some, but not all, of the introns in a naturally occurring gene, are within the scope of the term. Also within the term are DNA sequences which are transcribable to RNA but not necessarily subsequently translated to protein; such DNA sequences may encode antisense RNA and

25

30

ribozymes.

Another type of system involving inactivation of an "active" artificial male sterility gene is as follows. The first line contains:

5

- (i) an expressed gene giving rise to artificial male sterility; this gene may for example be the ribonuclease Barnase (from *Bacillus amyloliquefaciens*; Paddon *et al*, *J. Bacteriol.* 171 1185-1187 (1989)) driven by a tapetum-specific promoter, such as one of those designated A3 and A9 (WO-A-9211379); and

10

- (ii) an expressed restorer gene which restores male fertility; in the case of Barnase, this may be the Barstar toxin inhibitor (Hartley *Trends in Biochemical Sciences* 14 450-454 (1989)).

15

The first line will be male fertile because the Barstar (or other restorer) restores male fertility in spite of the expressed Barnase. The second line contains:

20

- a repressor gene, which represses the activity of the restorer gene (which may be for example a gene encoding a ribozyme or antisense to Barstar).

25

A hybrid formed by crossing the first and second lines will be male sterile, as the repressor gene will prevent the restorer gene from functioning, and therefore the artificial male sterility gene will itself function.

30

Another major group of embodiments within the invention involves the use, in one of the lines, of an inactivated phenotypic trait (for example, artificial male sterility) gene. The gene becomes active on crossing with the other line.

First, within this group, is the case where a stop codon (or more than one stop

codon) in a gene responsible for a desired phenotypic trait (such as a dominant AMS gene) in the first line is suppressed. The first line contains an AMS gene, or other phenotypic trait gene, coding for a protein; the gene is inactivated by one or more nonsense mutations, which may be the same as or different from each other. The second line contains a gene or genes coding for one or more suppressor tRNAs; these are designed to suppress the nonsense mutation(s) in the phenotypic trait (eg AMS) gene of the first line.

For practical reasons, if more than one mutation is needed in the AMS or other phenotypic trait gene of the first line, the mutations might all be identical, so that only a single type of suppressor tRNA is needed in the second line. Several copies of the tRNA gene can be used, if desired.

The genes can be introduced in plants by transformation (as may other foreign genes useful in this invention). In a simple implementation of this embodiment, the transformants have no phenotype which could be used to tell that the tRNA suppressor gene is working properly. This is inconvenient, because of the large variability of transgene expression between primary transformants due to position effects. However, for minimising any problem that there may be on this count, a reporter gene (such as a glucuronidase (GUS) gene inactivated by the same nonsense mutation as the male sterility or other phenotypic trait gene) may be linked to, or at least provided with, the suppressor tRNA gene so that the level of suppression in transformants of the second line can be evaluated. If the suppressor gene is functioning properly, the nonsense codon in the GUS gene will be suppressed and detectable glucuronidase will be expressed.

Transformants of the first line can be evaluated by performing the cross with the second line and screening for sterility, or another phenotypic trait, in the hybrid.

Restoration of fertility in a commercial hybrid male sterile plant can be achieved by a gene suppressing the AMS gene activity either at the protein level (such as

Barstar for Barnase) or at the transcription/translation level (such as ribozymes or antisense).

In more detail, a preferred implementation of an embodiment of the invention such as this and relating to male sterility is as follows. The first line (Line A) will express from the A9 promoter (which is tapetum specific and the subject of WO-A-9211379) a mutated barnase gene. The mutation will be introduced by *in vitro* mutagenesis. The mutation will change into an amber translational stop codon either the codon for isoleucine or the codon for tryptophan at position 4 or 35, respectively, of the mature barnase protein sequence. (This numbering does not take into account the artificial methionine codon introduced 5' during cloning of the ORF coding for the mature barnase protein.) The gene used in this embodiment is described in WO-A-9211379 and Paul *et al. Plant Mol. Biol.* **19** 611-622 (1992). All alterations refer to published sequences (from *B. amyloliquefaciens*; Paddon *et al, J. Bacteriol.* **171** 1185-1187 (1989)) with Genbank accession number M14442.

The second line (Line B) will express an amber suppressor tRNA which, when crossed to Line A, will insert at the artificial amber stop codon (UAG) of the barnase mRNA either a leucine or a tryptophan into the amino acid sequence. In the case of the leucine suppressor, the primary amino acid sequence of the active toxin will be different from the published one (isoleucine→leucine). The suppressor tRNAs will not allow (or at least reduce the occurrence of) a read through at the naturally occurring ochre translational stop codon (UAA) of the barnase mRNA.

The suppressor tRNA-leucine gene can be constructed *in vitro* from artificially made oligonucleotides according to the published sequence (Green *et al, Plant Mol. Biol.* **10** 13-19 (1987); Genbank accession number M21542) of the tRNA-leu3 gene from *Phaseolus vulgaris*. The construction process directly yields the amber-suppressor gene where the anticodon sequence is changed from CAA to

CUA.

The suppressor tRNA-tryptophan gene can be built by first isolating the wild type tRNA-tryptophan² gene of *Arabidopsis thaliana* (Lin *et al*, *Plant Mol. Biol.* 18 159-160 (1992); Genbank accession number: X5793) by DNA amplification from genomic DNA. The isolated gene will be converted by *in vitro* mutagenesis into an amber-suppressor gene where the anticodon sequence is changed from CCA to CUA.

Both suppressor tRNA genes can be expressed constitutively from their own (internal) promoter. To select the lines that express a functional amber-suppressor tRNA, an amber-mutated GUS gene transcribed from the cauliflower mosaic virus (CaMV) 35S promoter will be linked to the respective suppressor gene. Expression of GUS may thus allow the evaluation of the suppressor activity in the primary transformants of line B.

Lines A and B, respectively, can be obtained and propagated as homozygous lines. When crossed to each other, the resulting F1 offsprings, however, will be male-sterile due to tapetum-specific expression of an active barnase protein.

The invention, particularly in this embodiment, is not limited to the use of barnase as an AMS gene; other AMS genes can be used. AMS genes encoding very active proteins are preferred, since it can be assumed that efficiency of suppression may be low and so will the level of functional protein in the hybrid A \times B. Codons other than Ile or Trp can be mutated, provided an efficient suppressor tRNA gene can be made. Other stop codons (ochre or opal) can be used, provided efficient suppressor tRNA genes can be made.

Many plant nuclear tRNA gene sequences are publicly available and choice could be made between them; construction of an appropriate tRNA gene could be by using synthetic DNA deriving the sequence from the chosen public sequence and

changing the anticodon, for example by cloning from genomic DNA and normal gene using PCR technology and mutating the anticodon by *in vitro* mutagenesis.

5 It is expected that not all combinations of a mutation in an AMS gene and a suppressor tRNA would be efficient, and some routine experimentation could be necessary to choose between combinations. Such evaluation can be done as described in the examples below. In particular the efficiency of the stop signal used in the AMS ORF in the first line should be evaluated; the AMS should have an effect on fertility low enough for the plant to be at least partially fertile. The efficiency of stop suppression provided by the chosen suppressor tRNA gene
10 should also be evaluated; the activity of the AMS gene in the presence of the suppressor gene should be high enough to cause sufficient male sterility; therefore the use of a very active AMS gene is recommended.

15 To demonstrate the feasibility of this approach, it is of interest to note that, in unrelated work, Carneiro *et al*, *Plant Mol. Biol.* 22 681-690 (1993) have shown that the *in planta* expression of their suppressor tRNA_{amber}-leu3 gene alone had no deleterious effect on either growth or fertility of the transgenic tobacco plants. The authors also detected in protoplasts from those plants significant (20% of
20 GUS+ controls) suppression of electroporated GUS genes that contained amber mutations. The suppressor tRNA_{amber}-tryptophan2 was demonstrated by Franklin *et al*, *The Plant Journal* 2 583-588 (1992) to suppress an amber-mutated CAT (Chloramphenicol Acetyl Transferase) gene (up to 10% of CAT+ control) when co-electroporated into carrot protoplasts. Although the level of suppression seems
25 to be "very low" in transgenic plants (W. R. Folk, personal communication) as compared to protoplasts, it is expected in the present embodiment of the invention to be sufficiently high for toxins such as the barnase of which only one molecule is supposedly lethal for the cell in which it is expressed.

30 Another embodiment within the group involving the inactivation of a gene is based on transactivation of the expression of the gene. The gene may be an artificial

male sterility gene, or it may code for (or at least control) a phenotypic trait of interest. This embodiment of the invention is particularly suitable for expressing genes encoding heterologous proteins, particularly high value proteins, of interest. This embodiment of the invention, among others, is also suitable for expressing
5 genes giving rise to organ ablation.

In particular, the AMS or other (eg heterologous) gene is present in the first line but under the control of regulatory sequences (such as a promoter) which cannot function (either at all or sufficiently) for significant expression of the gene in the
10 first line. In the second line is a gene which, when present in the same plant as the AMS or other (eg heterologous) gene with its associated regulatory sequences, allows those regulatory sequences to function sufficiently to cause significant expression of the AMS or other gene. For example, the regulatory sequences in the first line may comprise a promoter which does not function with endogenous
15 RNA polymerase (such as the promoter from phage T7), and a gene encoding an RNA polymerase (which would be T7 polymerase in the specific case illustrated) which does function with the promoter may be present in the second line. For efficient use in eukaryotic cells the phage T7-RNA polymerase protein (T7RNP) should be modified so that it is targeted to the cell nucleus. This has been
20 achieved in plant cells (Lassner *et al*, *Plant Molecular Biology* 17 229-234 (1991)) by the addition of a nuclear-targeting signal from the large T-antigen of SV40 to the N-terminus of T7RNP.

This embodiment of the invention is particularly well suited to the production of
25 a protein encoded by a heterologous gene of interest, in the seed or other parts of hybrid F1 plants. Hybrid cells expressing the heterologous gene result from crosses between a first parental (eg female) line, designated line A, which contains the heterologous gene under the control of the bacteriophage T7 promoter, and a second parental (eg male) line, designated line B, which constitutively expresses
30 the T7 RNA polymerase. Neither line A nor line B expresses the heterologous gene of interest. The heterologous gene is expressed in F1 seeds harvested on line

A, though, and is expressed constitutively in F1 plants grown from those seeds. F1 seeds expressing the heterologous gene can be harvested for the processing and purification of the heterologous gene product. This binary system is typically adapted for expression of high added value compounds. Growers who cultivate
5 line A and line B grow only non-expressing plants, and so the system is susceptible of a high level of control.

To describe a particular embodiment in greater detail, a heterologous gene is under the control of the bacteriophage T7 promoter in the first line (line A). The
10 heterologous gene is not expressed in plant cells in line A, as the T7 promoter normally does not contain a binding site for plant RNA polymerase. In animal cells, non-specific transcription of T7 polymerase has been observed (Lieber *et al*, *Methods in Enzymology* 217 47-66 (1993)); if any non-specific transcription of the heterologous gene should occur in the plant, it is possible to suppress this non-
15 specific transcription by the use of modified T7 promoter. The modification may be one or more mutations in T7 promoter which block plant RNA polymerase transcription without modifying transcription mediated by the T7 RNA polymerase. These kinds of mutation in T7 promoter sequences have been made to prevent transcription of T7 by RNA polymerase of animal cells (Lieber *et al*, *Methods in*
20 *Enzymology* 217 47-66 (1993)).

The other parent in this embodiment is a transgenic, homozygous line, designated line B, which constitutively expresses T7 RNA polymerase in all tissues and organs, particularly in endosperm and embryo tissues; expression is stable and
25 transmitted through progenies. The T7 RNA polymerase may be under the control of a viral promoter, such as the p35S promoter from CaMV, a plant promoter, such as EF1 α , or a bacterial promoter which is transcribed in plant cells (such as MAS). A suitable promoter may be the plant aconitase promoter. The T7 RNA polymerase gene contains, at the N-terminal or C-terminal end of the coding
30 sequence, a nuclear location signal (NLS) sequence. The function of the NLS sequence is to direct expression of T7 RNA polymerase to the nucleus. The NLS

sequence may be a nucleotide sequence which codes for the subsequence Pro-Lys-Lys-Lys-Arg-Lys-Val of the large antigen of SV40; this subsequence has been shown to be sufficient to target T7 RNA polymerase to plant nuclei (Lasner *et al*, 1991).

5

Plants are obtained by crossing transgenic line A and transgenic line B. Various techniques can be used to ensure a specific cross between line A and line B, including: artificial male sterility systems, cytoplasmic or nuclear male sterility, and manual or chemical sterilisation of the female line. Pollen from the male line will fertilise the female line. Seeds which contain the expression product of the heterologous gene will be harvested on the female line.

10

Expression of the heterologous gene is restricted to tissues coming from fertilisation, namely the zygote and the endosperm. There is no expression in tegument or maternal tissues. In zygotic tissues (cotyledons, roots and apices) and endosperm of the F1 seeds, the T7 RNA polymerase, which is expressed in the nucleus, specifically recognises the T7 promoter and transcribes the heterologous gene of interest to form mRNA. T7 RNA polymerase, when functional, allows a high level and stable gene expression in seeds. If F1 seeds are germinated and grown, the heterologous gene is expressed in all tissues and organs of the plant, particularly in cotyledons, young plantlets, roots, leaves, stems and flowers.

15

20

The heterologous gene may be a mammalian or microorganism gene encoding a protein, for example for pharmaceutical or cosmetic use. However, the invention is not at all limited by the purpose or function of the expression product of the heterologous gene. For example, the heterologous gene may encode an industrial protein such as an enzyme or other bio-product; or the heterologous gene may encode an enzyme for use *in situ* to produce a substance of interest or to modify the primary or secondary metabolism of the plant to produce an added value compound.

25

30

It is equally contemplated in the present invention that the heterologous gene may not have a protein expression product. For example, the heterologous gene may be a gene coding for antisense RNA or a ribozyme. Antisense RNA and ribozymes may for example, like enzymes discussed in the preceding paragraph, modify the metabolism of the plant, or the content or nature of plant molecules such as polysaccharides or fatty acids, to produce food or feed with nutritional or other economic benefits or to produce plants for industrial, agricultural or environmental uses.

Another example of the present category of embodiments would be the use in one line of a promoter for the AMS (or other heterologous) gene which is not active in the absence of its cognate *trans*-acting transcription factor; in the second line would be a tissue-specific gene encoding the *trans*-acting transcription factor.

In the embodiments of this group which relate to male sterility, restoration of male fertility can be achieved, as described above, by suppressing the AMS activity.

A third embodiment within the group involving the inactivation of an active artificial male sterility gene, or other heterologous gene, is based on transactivated specific splicing of an inactivating sequence (such as an intron) placed in the gene in question.

In this embodiment, the first line, Line A, contains a gene of interest, such as an AMS gene, interrupted by an inactivating sequence which is capable of being spliced out. The inactivating sequence may be an intron or any other sequence which is capable of being spliced out by, say, a maturation enzyme. The intron may be a yeast mitochondrial intron, such as a derivative of the intron bI4 of the *Saccharomyces cerevisiae* cytochrome b gene. In another implementation of this embodiment, the intron may be the rRNA group I intron from *Neurospora crassa*,

which is spliced by the protein CYT18. The gene of interest is inactivated by the intron.

5 The second line, Line B, contains a gene encoding an enzyme capable of splicing out the inactivating sequence. In the specific case of the yeast mitochondrial intron discussed above, the enzyme would be the corresponding yeast maturase (eg the coding sequence from intron bI4 as above), engineered to have the universal genetic code, to have a nuclear localisation signal, and expressed in the same tissue as the gene of interest. As a generality, the maturase has no effect on the plant,
10 so phenotypic normality is preserved. In the hybrid A \times B, the intron is spliced by the maturase and the gene of interest is functional. In the case of the rRNA group I intron, the gene needed for splicing encodes the CYT18 protein, as has been described.

15 For male sterility embodiments, restoration of male fertility can, as described above, be achieved by suppressing the AMS activity.

In another important embodiment, the desired phenotypic trait is seed specific expression of one or more proteins. This can be useful for the production of
20 pharmaceutically useful proteins in seeds. Examples of such pharmaceutically useful proteins include lymphokines, EPO, tPA, interferons, blood factors and/or enzymes.

In another embodiment, the phenotypic trait results from the non-expression of a
25 gene. This can be brought about when, for example:

- (i) the first line comprises an antisense sequence for the gene whose non-expression gives rise to the phenotypic trait, the antisense sequence being under the control of a promoter or other regulatory sequence which cannot

function for significant expression of the antisense sequence; and

(ii) the second line comprises a gene which, when present in the same plant as the antisense sequence with its associated regulatory sequence, allows that regulatory sequence to function sufficiently to cause significant expression of the antisense sequence, such expression leading to down regulation of the gene whose non-expression gives rise to the phenotypic trait.

Plants obtainable using the methods of the invention form a second aspect of the invention.

Artificially male sterile plants produced using the methods of the invention are the result of a cross between two normal fertile, homozygous plants referred to above as the first line and the second line (or, in specific embodiments, Line A and Line B). This cross between the first and second lines would have to be performed in a manner to prevent self-pollination, but only on the small scale needed to produce the basic seeds. Self-pollination can be prevented by using chemical, mechanical or manual castration of one line and physical separation in the field of the other line (the pollinator). Careful examination of the hybrid seed production process leads to the conclusion that a manual cross at the basic seeds production step is practical and economical. The cost of crossing manually is largely overcome by the advantages of obtaining a genetically homogenous batch of (male sterile) female parent seeds which can be used directly in the hybrid seeds production field, without selection, and which cannot be easily reproduced. An added advantage is that this cross could be the cross of a breeding scheme (as in 3-ways hybrids commonly used), in which case there is no added cost beyond that of the normal basic seed production process.

Similar considerations apply, *mutatis mutandis*, to other plants of the invention having different phenotypes.

Heterologous DNA can be introduced in the desired plant by transformation, and the transgenics are bred to homozygosity. Preferably, DNA is transformed into plant cells using a disarmed Ti-plasmid vector and carried by *Agrobacterium* by procedures known in the art, for example as described in EP-A-0116718 and EP-A-0270822. Alternatively, the foreign DNA could be introduced directly into plant cells using an electrical discharge apparatus. This method is preferred where *Agrobacterium* is ineffective, for example where the recipient plant is monocotyledonous. Any other method that provides for the stable incorporation of the DNA within the nuclear DNA of any plant cell of any species would also be suitable. This includes species of plant which are not currently capable of genetic transformation.

Although the usefulness of the invention is not especially limited to any particular species or other taxonomic grouping, it is expected that the greatest use of the invention will be with economically important crops. Examples include maize, tomato and wheat.

Male sterile plants in accordance with the invention are useful as female parents in the production of commercial F1 hybrid seed. The precise details for this final cross will vary from crop to crop. For maize, the male parent (designated plant C) will be planted in one row alternating with several rows of female parent (designated plant AB). After pollination the male parent rows are crushed, and seeds harvested only from the female rows. No chemical treatment of the production field is needed, and except for the absence of manual detasseling, the process is very similar to the one currently used in the field.

The female parent cannot be reproduced since it is made through a cross that the hybrid seed producer cannot perform. The hybrid seeds obtained (designated ABC) will segregate male sterility. The actual frequency of male sterile plants in the hybrid seeds population will depend on the location of the heterologous DNA in the genomes of the first and second lines, as described above. The highest frequency of male sterile would be if the two heterologous genes segregate independently (are located on different linkage groups); it would then be 25%. Because wind driven cross pollination is very efficient in maize, in practical terms the population would behave as a 100% fertile population, and a restorer gene in parent C is not compulsory. If it is however desired, it can be done as described below for tomato.

In the case of tomato, male sterile seeds in accordance with the invention can be planted in a hybrid seed-production glasshouse as the female parent (plant AB), and pollination by pollen from the male parent (plant C) is done. No chemical treatment, no sorting of plants, and no emasculation are needed. In this case, the hybrid plants obtained should preferably be 100% fertile since cross pollination is not very effective naturally in the tomato production field. To achieve that, it is possible to rely on two techniques. First, in a genetic approach, the heterologous DNA in plant A (gene A) and the heterologous DNA in plant B (gene B) are located at tightly linked loci on opposite chromosomes of a given pair, and therefore have very little probability of cosegregating in the hybrid plant (as explained in WO-A-9201799). Secondly, plant C may be engineered to express a restorer gene; any dominant gene which prevents gene A or gene B activity is suitable. A gene expressing Barstar (a proteinaceous inhibitor of Barnase (Hartley *Trends in Biochemical Sciences* 14 450-454 (1989)) is appropriate (see for example EP-A-0412911).

To obtain a phenotype using the described binary systems, one combines the two

genes in the same plant by crossing two plants, usually primary transformants or selfed progeny of primary transformants. Because of the well known "position effect", not all primary transformants containing the first gene will be suitable for crossing to all primary transformants containing the second gene, and parent plants
5 will generally have no conveniently detectable phenotype allowing to screen the suitable plants among them. To identify the suitable parents among the independent primary transformants, many crosses are performed, and the hybrids obtained are then evaluated for the desired phenotypic trait. Although this can be done, it is a lengthy process. One way to implement the invention more quickly
10 is the following:

Target plant tissue is transformed with the first gene, but not allowed to regenerate into plants. The regeneration capacity of the tissue is retained. The transformed tissue is then transformed with the second gene, using a different selectable marker
15 if needed. The transformed tissue, now containing the two genes at independent positions in the genome, is then allowed to regenerate a whole fertile plant. Among the plants obtained in that way, some will have the desired phenotypic trait as a consequence of them having the two genes at suitable positions in the genome. In the progeny of such a plant, segregation plants having only the first gene or
20 only the second gene and not having the desired phenotypic trait can be identified. Such plants are then multiplied and used as parents in the cross to produce the hybrid plant with the desired phenotype. If an extensive back-cross process is required to convert the primary transformant to a better agronomic variety, as is often the case for example with maize, this back-cross process can be done on the
25 plant containing the two genes and showing the phenotype. When an acceptable elite variety is obtained, usually after 3 to 6 steps of back-cross, the two genes are allowed to segregate and the parent plants are identified among the segregants. The parent plants are then multiplied, and later used to produce the desired hybrid plant, showing the desired phenotype. If, however, it is desired that the two

parents are different, the back-cross process can be done using a different recurrent pollinator on each parent (having one of the two genes and not showing the phenotype) and not on the original transformant (having the two genes and showing the phenotype).

5

Plants useful as either the first or second lines, as used in the methods of the invention, form a further aspect of the invention.

10

According to another aspect of the invention, there is provided propagating material, particularly seed, of a plant in accordance with the invention.

15

According to a fifth aspect of the invention, there is provided a hybrid plant obtainable by crossing a male plant with a male-sterile plant in accordance with the invention.

20

In yet a further aspect of the invention, there is provided a method of producing a plant having a desired phenotypic trait, the method comprising crossing a first line and a second line wherein each of the first and second lines does not have the phenotypic trait in question, and wherein at least one of the first and second lines is transgenic.

25

Among the phenotypic traits that could be created using some of the binary systems that we describe, a useful trait is cell ablation.

Some plant tissues or organs can be undesirable. Examples of these include seeds in fruits (grapes), hair on fruit skin (peaches), or petals in oilseed rape (as they promote propagation of the pathogenic fungus *sclerotinia*). However, in many cases it would be desirable to limit this trait to hybrid plants, produced by crossing parents with no altered phenotypes.

This can be achieved by using a binary system made for example of an inactive toxic gene under control of a promoter specific of the tissue or organ to be destroyed, supplied by the first parent plant, activated in the hybrid plant by the activator gene supplied by the second parent.

5

Preferred genes are the Barnase ORF inactivated by one or more stop mutation, under control of the appropriate tissue specific promoter, and a suppressor tRNA gene able to read the stop codons.

10 Another example of a suitable system consists of a non-expressed toxic gene supplied by the first plant, which expression is activated in the hybrid in a tissue specific manner by a tissue specific transactivator supplied by the second parent.

15 Preferred genes are the Barnase ORF under control of a suitably modified T7 promoter, and a T7RNA Polymerase gene under control of a promoter specific for tissue to be destroyed. Another possibility of the same example is to use the CaMV translational transactivator (gene VI) under control of a tissue specific promoter to activate translation of a toxic ORF present as the second cistron in a mRNA expressed in the tissue to be destroyed. Another possibility relies on intron
20 splicing using a tissue specific maturase as explained previously.

Preferred features for each aspect of the invention are as for each other aspect, *mutatis mutandis*.

25 The invention will now be illustrated by the following examples. The examples refer to the drawings, in which:

FIGURE 1A: shows the scheme for cloning transactivator reporter gene;

FIGURE 1B: shows the scheme for cloning the AMS mutant genes;

FIGURE 2A: shows the scheme for cloning the transactivator and reporter genes;

5

FIGURE 2B: shows the scheme for cloning an AMS mutant gene (Barnase AMS);

FIGURE 3: is a description of pGA492 Hygro;

10

FIGURE 4: shows the structure of the A9 promoter-C103 chimeric gene excised from pWP80 in Example 7;

15

FIGURE 5: shows the alignment of *A. thaliana* ms2 with *B. napus* C103 DNA.

EXAMPLE 1

20

tRNA Mediated Suppression of a Stop Codon in an AMS Gene

25

A suitable Artificial Male Sterility (AMS) gene coding for a protein which prevent male fertility can be made inactive by substitution of 1-3 bases in the coding sequence (Open Reading Frame ORF) so that a valid codon is transformed into a Stop codon (TAA: ochre, TGA: opal, TAG: amber). This mutated gene (gene A) is therefore inactive and plants containing it (plant A) are fertile. A suppressor tRNA can be engineered which will read the Stop codon as an amino acid codon and therefore allows translation of the mutated ORF. This gene (gene B) in itself

will have no effect on the plant that expresses it (plant B) as shown for example in tobacco by Carneiro *et al.*, (*Plant Mol. Biol.* 22 681-690 (1993)). The product of a cross between A and B will express the AMS ORF and be sterile.

5 Specifically, the codon coding Trp at amino acid position 37 of the barnase ORF encoding the mature protein (Paddon and Hartley, *Gene* 40 231-239 (1986); Hartley *J. Mol. Biol.* 202 913-915 (1988) can be converted into an amber stop codon. Some other minor sequence alterations are also introduced as follows.

10 The sequence surrounding the amber codon is modified to facilitate identification of the correct mutant, and to change it to a sequence closer to the plant consensus sequence for end of ORF signals (sequences start at the first base of the Trp codon 35):

15

Normal nucleotide sequence: TGGGTGGCATCAAAAGGGAACCTTGCAGAC

Normal aa sequence: TrpValAlaSerLysGlyAsnLeuAlaAsp

Mutated nucleotide sequence: TAGATTGCATCAAAAGGGAACCTTGCAGAT

Mutated aa sequence: AmbIleAlaSerLysGlyAsnLeuAlaAsp

20

The mutated sequence has the ability to be translated into an active barnase protein in the presence of an amber suppressor tRNA is demonstrated in *E. coli*. When expressed in *E. coli* from the plant promoter A9, which has by chance some significant transcriptional activity in *E. coli*, the mutated barnase gene is toxic to
25 the host cells if the barstar region is deleted. This demonstrates that the introduced amber codon is suppressed to some extent, even in the absence of known suppressor tRNA genes. This suppression could be caused by translation mistakes. It also demonstrates that the other mutations which were introduced in addition to the amber codon did not impair the activity of the barnase protein. However,
30 mutant constructs having lost toxicity could then be isolated only from strain

MC1061 which has no sup^tRNA genes; and in these mutants no other change than the introduced mutations were found within the coding region of the barnase gene. When reintroduced into strains MC1061 and LE392, these mutant constructs were non toxic to strain MC1061 which is not known to have suppressor tRNA genes, but still toxic to strain LE392 which has genes for tRNA sup^E44 (translating amber as glutamine) and sup^F58 (translating amber as tyrosine). It seems therefore that the spontaneous mutation selected in these constructs decreases the level of expression of the mutated barnase gene, thus making the tRNA suppressor absolutely necessary for obtaining a toxic level of barnase. The genotypes of the bacterial strains are described in "Molecular Cloning: A Laboratory Manual", Sambrook *et al*, Cold Spring Harbor Laboratory Press, USA, 1989, and the strains are available from public collections, as will be known to those skilled in the art.

This result demonstrates the feasibility of the system, and also suggests that a tighter system could be useful. A second amber codon is therefore engineered at the codon for Trp at position 71 of the barnase mature protein, as follows (sequence starts at 1st base of codon 70):

Normal nucleotide sequence: ACATGGCGTGAA
Normal aa sequence: ThrTrpArgGlu
Mutated nucleotide sequence: ACCTAGAGAGAA
Mutated aa sequence: ThrAmbArgGlu

The mutated genes described are expressed under control of the tapetum specific promoter A9 (WO-A-9211379) and the resultant gene is introduced into *Arabidopsis thaliana*. Figure 1 shows the scheme used to clone the genes in the expression vector, and to transfer the construct in the plant transformation vector pBin19. Transgenic plants are obtained by *Agrobacterium*-mediated transformation and are fertile; they are allowed to self, and selfed seeds are collected; the seeds

obtained are segregating the transgene, and plants homozygous for the transgene (plant A) are identified.

The gene coding for tRNA Trp2 (Tsai Yun Lin *et al*, *Plant Mol. Biol.* 18 159-160 (1992)) has been cloned from *Arabidopsis thaliana* ecotype C24, by PCR from genomic DNA, using the published sequence to design the following primers:

TW1: 5'TATCGGATCCAGGAGGAAGCAAAGCAGTACC

TW2: 5'CCACTAGTAGATCTCCACTTCCCTTCCTTTGTTGGA

The anticodon region is then converted by *in vitro* mutagenesis from CCA to CTA. The resulting mutated tRNA (SupamtRNA^{Trp}) is now able to read the amber codons as Trp codons. The suppressor tRNA gene is introduced in *Arabidopsis*, after being cloned in plant transformation vector pBin19 as shown schematically in Figure 1. The T-DNA in which the suppressor tRNA gene is inserted also contains a constitutive 35S-GUS gene inactivated by a Trp to Amb mutation at codon 35. This mutated GUS is used as a reporter gene for suppressor tRNA activity in the primary transformants.

A) Numbering and construction of genes (Figures 1A and 1B)

The inactivated AMS gene (Figure 1B):

The mutated A9-Barnase (Trp35amber) was obtained by PCR mutagenesis from the pWP127 (Paul *et al*, *Plant Molecular Biology*, 19:611-622 (1992)), and the mutagenised Barnase-Barstar fragment XbaI-BglII was inserted in the XbaI-BamHI sites of p1415 (described below), yielding p2013. One further round of mutagenesis from p2013 yielded p2017:A9-Barnase (Trp35amber Trp71amber). These genes were then inserted in the HindIII site of pBin19 (Bevan *et al*, *Nucleic*

Acids Research, 22:8711-8721 (1987)) as HindIII fragments, yielding p3086 and p3088 respectively. Description of p1415:p1415 is a derivative of pWP91, where the unique EcoRV site located 3' of the CaMB transcription terminator is replaced by a HindIII site. The cassette containing the A9 promoter and the CaMV terminator can therefore be recovered from P1415 as a Hind III Fragment. pWP91 is a derivative of pJIT60 where the duplicated 35S promoter region is replaced by a 934 bases A9 promoter region from pWP75 (described in *Plant Molecular Biology*, 19, 611-622 (1992)). pWP91 therefore contains a cassette made of the A9 promoter and the CaMV terminator. pJIT60 is a derivative of pJIT30 (described in *Plant Molecular Biology*, 15, 127-136 (1990)), where the 35S promoter of pJIT30 has been duplicated.

The transactivator gene and the reporter gene (Figure 1A):

Trp Suppressor tRNA: the PCT amplified fragment was cloned in pBlueScript SK+ (Stratagene) as shown in the figure, yielding p3071.

A BamHI-SpeI insert from p3071 was reinserted in sites BglII-SpeI of p3071, yielding p3081 which contains tandem repeat of the suptRNA.

A reporter gene was built by mutagenising Trp codon 35 to create an amber codon in the GUS gene (obtained from pBI121 (*Jefferson et al*, *EMBO Journal* 8:3901-3907(1987)), and then cloning the mutagenised gene (with all the regulatory sequences) in pBlue Script SK+, yielding p2010. The mutated GUS gene was then inserted as a HindIII-EcoRI fragment in the HindIII-Eco RI sites of pBin 19 yielding p3092.

The suptRNA genes were inserted next to the reporter gene: a BamHI(Klenow)-SpeI fragment from p3071 or p3081 was inserted in sites EcoRI(Klenow)-SpeI of p2010, yielding p3094 and p3096 respectively.

Transfer of this construct to binary vectors: HindIII linearised plasmids p3094 and p3096 were inserted in the HindIII site of pBin19, yielding p3108 and p3109 respectively. These plasmids contain the suptRNA gene(s) and the reporter gene. They were introduced into *Agrobacterium tumefaciens* strain AGL1 ("AGL1") by electroporation. The HindIII-SpeI insert from p3094 and p3096 was also inserted in the HindIII-XbaI site of another binary vector: pGA492Hygro (described below and in Figure 3), yielding p3112 and p3113 respectively. These plasmids can be introduced in AGL1 by triparental mating.

Description of pGA492Hygro: it is a derivative of pGA492 (described in An *et al*, 1986, *Plant Physiology*, 81, 86-91) where a Hygromycin resistance gene made of the 35S promoter, the HygB ORF and the nos terminator has been inserted as a SacI-EcoRI fragment in the SacI-EcoRI sites of pGA492, deleting approximately 280 bases from pGA492 including the 5'end of the CAT ORF.

Combination of the AMS gene and the transactivator gene on the same T-DNA (Figure 1B):

The HindIII fragment of p2013 containing the A9-Barnase(Trp35amber) gene was inserted in the HindIII site of p3112 and 3113 yielding p3121 and p3119 respectively. Similarly the HindIII fragment of p2017 containing the A9-Barnase (Trp35amberTrp71amber) gene was inserted in the HindIII site of p3112 and p3113, yielding p3114 and p3120 respectively. These four plasmids were introduced into AGL1 by triparental mating.

B) List of constructs introduced in plants and description

Genes are shown with their regulatory sequences (promoter and terminator); Genes are separated by "/".

- p3086 A9-Barnase(Trp35amber)-CaMV
 p2088 A9-Barnase(Trp35amber Trp71amber)-CaMV
 p3092 35S-GUS(Trp35amber)-Nos
 p3108 35S-GUS(Trp35amber)-Nos/TrpsuptRNA/BlueScript SK +
 5 p3109 35S-GUS(Trp35amber)-Nos/TrpsuptRNA/TrpsuptRNA/Blue Script
 SK +
 p3112 35S-GUS(Trp35amber)-Nos/TrpsuptRNA
 p3113 35S-GUS(Trp35amber)-Nos/TrpsuptRNA/TrpsuptRNA
 P3121 A9-Barnase(Trp35amber)-CaMV/35S-GUS(Trp35amber)
 10 -Nos/TrpsuptRNA
 p3119 A9-Barnase(Trp35amber)-CaMV/35S
 -GUS(Trp35amber)Nos/TrpsuptRNA/TrpsuptRNA
 p3114 A9-Barnase(Trp35amber Trp71amber)-CaMV/35S-
 GUS(Trp35amber)-Nos/TrpsuptRNA
 15 p3120 A9-Barnase(Trp35amber Trp71amber)-CaMV/35S-
 GUS(Trp35amber)-Nos/TrpsuptRNA/TrpsuptRNA

C) Description of plants

- 20 Transgenic Arabidopsis plants were obtained by root transformation using
 Agrobacterium and standard methods.
 The plants were evaluated for fertility and seeds harvested from fertile plants.
 Plants containing the mutated GUS gene were also assayed for GUS gene
 expression by incubating some plant tissue (leaf and/or flower) in X-Gluc, using
 25 standard methods. GUS enzyme activity was detected by a blue staining. Most
 of the transformed plants had some level of GUS enzyme more noticeable in young
 anthers which was called background GUS("bG"). This level is probably caused
 by endogenous suppression of stop codons or by translation mistakes, as it could
 be detected also in some plants containing the mutated GUS gene only, and no

exogenous suppressor tRNA. In the presence of the exogenous suppressor tRNA, a significant fraction of the plants had higher level of GUS activity: above background GUS "abG", as shown in the following table:

5	<u>Plasmids</u>	<u>Description of the plants:</u>
	p3086:	21 plants obtained; 21 fertile.
	P3088:	22 plants obtained; 21 fertile; 1 sterile.
	p3092:	11 plants obtained; 11 fertile.
10		1 plant out of 10 tested shown bG.
		No abG found.
	p3108:	19 plants scored for fertility; 19 fertile; 1 sterile (flower abnormalities).
		4 plants (1 sterile) out of 22 tested show abG.
15	p3109:	21 plants scored for fertility; 21 fertile.
		10 plants out of 22 tested show abG.
	p3120:	4 plants obtained; 2 male sterile, 2 fertile.

D) Plant propagation, genetic analysis and crosses.

20

Seeds from fertile transgenic plants (T0) have been harvested (T1 seeds), planted and homozygous T1 plants can be identified by following the segregation of the nptII (Kanamycin resistance) gene in the T2 generation.

25 Homozygous T1 plants containing p3086 or p3088 can then be crossed with homozygous T1 plants containing p3108 or p3109. The hybrid seeds (F1) are harvested and planted on soil. F1 families are scored for fertility. When both parents contain an efficient transgene the family has 100% sterile plants.

E) Conclusion.

The experiment demonstrates that:

5 The AMS gene, inactivated by 1 or 2 stop codons, has no detrimental effect on the plant fertility. It can be transactivated by suppressor tRNA in bacteria. Therefore plant A can be obtained.

10 Suppressor TRNA (the transactivator gene) has no effect on plant fertility but is able in a number of plants to suppress a stop codon in the GUS gene as shown by staining. the transactivator is efficient. Plant B can therefore be obtained.

15 The inactivated AMS gene and the suppressor TRNA gene put together by cotransformation on the same T-DNA (p3120) cause male sterility in a number of plants, showing that the presence in the same genome of the 2 genes is causing male sterility.

20 A male sterile plant can therefore be obtained by crossing 2 fertile plants containing an inactivated AMS gene and a transactivator respectively.

EXAMPLE 2

tRNA Mediated Suppression of a Stop Codon in an AMS Gene

25 The procedure of Example 1 was followed, except that codon No. 4 in the sequence of the mature barnase protein is mutated so that the Ile codon is converted to amber. The sequence surrounding the amber codon is modified as follows, for the reason given in Example 1 (sequences start at first base of codon 1 of the mature protein):

Normal nucleotide sequence: GCACAGGTTATCAAC

Normal aa sequence: AlaGlnValIleAsn

Mutated nucleotide sequence: GCACAAGTGTAGAAC

Mutated aa sequence: AlaGlnValAmbAsn

5

The results obtained in *E. coli* are the same as those described in Example 1. A second amber mutation is introduced at the codon for Leu at position 95 of the barnase mature protein as follows (sequences start at first base of mutagenised Leu codon 95):

10

Normal nucleotide sequence: CTGATTTACAAA

Normal aa sequence: LeuIleTyrLys

Mutated nucleotide sequence: TAGATTTACAAA

Mutated aa sequence: AmbIleTyrLys

15

A) Numbering and construction of genes (Figures 2A and 2B)

The inactivated AMS gene (Figure 2B):

The mutated A9-Barnase (Ile4amber) was obtained by PCR mutagenesis from pWP127, and the mutagenised Barnase-Barstar fragment XbaI-BglII was inserted in the XbaI-BamHI sites of p1415, yielding p2014. This gene was then inserted in the HindIII site of pBIN19 as a HindIII fragment, yielding p3087.

20

The transactivator gene and the reporter gene (Figure 2A):

Leu Suppressor tRNA: the synthetic DNA fragment was cloned in pBlueScriptSK+ as shown in figure 2A, yielding p3062 and p3063 (2 identical clones).

25

A BamHI-BglII insert from p3063 was re-inserted in site BglII of p3063, yielding p3077 which contains a tandem repeat of the suptRNA.

30

A reporter gene was built by mutagenising Ile codon 123 to create an amber codon in the GUS gene (obtained from pBI121), and cloning the mutagenised gene (with all the regulatory sequences) in pBlueScript SK+, yielding p3078. The mutated GUS gene was then inserted as a Hind III-EcoRI fragment in the HindIII-EcoRI sites of pBin 19 yielding p3093.

The suptRNA genes were then inserted next to the reporter gene: an EcoRI-SpeI fragment from p3062 or p3077 was inserted in sites EcoRI-SpeI of p3078, yielding p3083 and p3082 respectively.

Transfer of this construct to binary vectors: HindIII-SpeI fragments from p3083 and p3082 were inserted in the HindIII-XbaI sites of pBin19, yielding p3090 and p3089 respectively. These plasmids contain the suptRNA gene(s) and the reporter gene. They were introduced into AGL1 by electroporation.

Combination of the AMS gene and the transactivator gene on the same T-DNA (Figure 2B):

The HindIII fragment of p2014 containing the A9-Barnase (Ile4amber) gene was inserted in the HindIII site of p3090 yielding p3102. This plasmid was introduced in AGL1 by electroporation.

B) List of constructs introduced in plants and description.

Genes are shown with their regulatory sequences (promoter and terminator); Genes are separated by "/".

p3087: A9-Barnase(Ile4amber)-CaMV

p3093: 35S-GUS(Ile123amber)-Nos

p3090: 35S-GUS(Ile123amber)-Nos/LeusuptRNA
 p3089: 35S-GUS(Ile123amber)-Nos/LeusuptRNA/LeusuptRNA
 p3102: A9-Barnase(Ile4amber)-CaMV/35S-GUS(Ile123amber)
 -Nos/LeusuptRNA

5

C) Description of plants.

Transgenic plants were obtained and scored as in Example 1.

10	<u>Plasmid</u>	<u>Description of the plants</u>
	p3087:	22 plants obtained; 21 fertile; 1 sterile with flower abnormalities.
	p3093:	16 plants obtained; 16 fertile
15		8 out of 13 plants tested show bG. No abG observed.
	p3090:	19 plants obtained; 15 fertile; 4 sterile. 6 plants (including the 4 sterile) show abG.
	p3089:	8 plants obtained; 5 fertile; 2 sterile; 1 sterile with flower abnormalities.
20		No abG observed.
	p3102:	8 plants obtained; 4 sterile, 4 fertile;

25 The toxicity of the LeusuptRNA is unexpected as it is in contradiction with published data. It can be explained by taking into account the dual localisation (cytosolic and mitochondrial) of the bean LeutRNA chosen for the experiment: the presence of a suppressor tRNA in the mitochondria where the pool of tRNAs is limited might be deleterious for the cell. However, some plants expressing the LeusuptRNA have a normal phenotype and can be used in a cross to transactivate

the inactivated AMS gene. And furthermore: the presence on the same T-DNA of the 2 genes (in p3102) increases the frequency of sterile plants showing that the transactivation is efficient.

5 **D) Plant propagation, genetic analysis and crosses.**

As in Example 1, seeds from fertile transgenic plants (T0) were harvested (T1 seeds) and planted. Heterozygous and homozygous T1 plants can be identified by following the segregation of a single *nptII* (Kanamycin resistance) locus in the T2
10 generation.

Kanamycin resistant individuals from a T1 population from a primary transformant containing p3087 were crossed as female to individuals of T1 populations from 3 primary transformants containing p3090 and expressing the tRNA gene (as shown
15 by a RT-PCR experiment). The hybrid seeds (F1) were obtained and planted on soil.

Sterile plants in the F1 families were identified with expected frequencies:

- 20 0% if one parent is Kanamycin sensitive;
25% if both parents are heterozygous for the *nptII* gene;
50% if one parent is homozygous for the *nptII* gene;
100% if the two parents are homozygous.

E) Conclusion

25

The experiment demonstrates that the AMS gene, inactivated by 1 stop codon, has no effect on the plant fertility. It can be transactivated by suppressor tRNAs in bacteria. Therefore plant A can be obtained.

The suppressor tRNA has a strong, gene dosage dependent effect, on plant viability and fertility. It is nevertheless possible to obtain normal plants expressing the suppressor tRNA by screening a large population of transformants. The suppressor tRNA is efficiently transactivating a mutated reporter gene. Plant B
5 can therefore be obtained.

When plant A was crossed to plant B, male sterile F1 plants were found in predicted ratios. This demonstrates the feasibility of generating a homogeneous population of male sterile plants from a cross of a homozygous plant A expressing
10 the transgene A with a homozygous plant B expressing the transgene B.

EXAMPLE 3

T7 RNA Polymerase-Mediated Expression of an AMS Gene

15

Construction of an A9 promoter-modified T7 RNA polymerase chimeric gene.

For efficient use in eukaryotic cells, the phage T7-RNA polymerase protein (T7RNP) must be modified so that it is targeted to the cell nucleus. This has been achieved in mammalian (Lieber *et al*, *Nucleic Acids Research* 17 8485-8493
20 (1989)) and plant cells (Lassner *et al*, *Plant Molecular Biology* 17 229-234 (1991)) by the addition of a nuclear-targeting signal from the large T-antigen of SV40 to the N-terminus of T7RNP. A similar SV40 leader-T7RNP gene fusion was constructed by Dr. Andrzej Pluciennicz in the following manner:

25 The T7RNP gene was isolated as an *Nru*I, *Bam*HI fragment from plasmid pGP1-2 (Tabor and Richardson, *Proc. Nat'l. Acad. Sci. USA* 82 1074-1078 (1985)) and cloned between the *Acc*I (rendered flush with Klenow) and *Bam*HI sites of pUC19 forming the plasmid pT75. A leader sequence from the SV40 large T-antigen gene was then cloned in front of the *Nru*I site of pT75, forming pT751.

The modified T7RNP gene of pT751 is then placed under control of the tapetum-specific A9 promoter. The *Xba*I-*Bam*HI fragment containing the modified T7RNP gene is cloned between the *Xba*I and *Bam*HI sites of pWP91 (described in WO-A-9211379) forming pWP180 (Figure 2A). The A9 promoter-T7NP chimeric gene is then cloned as an *Xho*I fragment into the *Sal*I site of pSCV-nos-nptII (pSCV-nos-nptII was made by cloning a nos promoter-nptII-nos terminator chimeric gene between the *Eco*RV and *Eco*RI sites of pSCV1 (see Firek *et al*, *Plant Molecular Biology*, 22: 129-142 (1993) for information on pSCV1). The resulting plasmid (pWP180-SCV) is then transformed into plants and bred to homozygosity (plant A).

Construction of a T7 promoter PR-glucanase chimeric gene.

An *Eco*RI, *Xho*I fragment containing the A9 untranslated 5' leader sequence and the 5' region of the PR glucanase gene from pDW80PR (Worrall *et al*, *The Plant Cell* 4 759-771 (1992)) is cloned between the *Eco*RI, *Sal*I sites of the vector pTZ18 (Pharmacia Ltd) forming pWP178. Transcription by T7-RNA polymerase from the T7 promoter produces RNA that is uncapped and thus may be unstable or poorly translated in eukaryotes. Addition of a 5' leader sequence that allows cap-independent translation, such as the Tobacco Etch viral leader (TEV) (Carrington and Freed, *Journal of Virology*, 64: 1590-1597 (199)), markedly increases translation of protein from RNA transcribed by T7-RNA polymerase (Tuttle *et al*, *4th International Congress of Plant Molecular Biology*, Abstracts p478 (1994)). The TEV leader sequence is therefore cloned as an *Eco*RI-*Nco*I fragment between the *Eco*RI and *Nco*I sites of pWP178, thus removing the A9-leader, forming pWP178-TEV.

A modified T7 primer:

5' GGGGCTCGAGTTAATACGACTCACTATAGGG 3' (an *Xho*I site added 5' to the T7 promoter)

and the M13 20' primer:

5

5' CGTTGTAAAACGACGGCCAG 3' (primers outside the polylinker of pTZ18)

are then used in a polymerase chain reaction to obtain a T7 promoter TEV leader-PRgluc' fragment that is cloned into pBluescript II KS- (Stratagene Ltd) as an *Xho*I, *Hind*III fragment, forming pWP188-TEV. The *Kpn*I-*Nco*I fragment of pWP188-TEV is then used to replace the *Kpn*I-*Nco*I A9 promoter-leader fragment of pDW80PR, forming pWP222. Primers:

15

5' CCGCATGCGATCCGGCTGCTAACAAAGCC 3' and
5' GGATATCAGATCTCGATCCGGATATAGTTCC 3'

are used in polymerase chain reaction with plasmid ET-21-a (Novagen) as template and the resulting T7 terminator sequence is cloned as a *Sph*I, *Eco*RV fragment between the *Sph*I and *Eco*RV sites of pWP222, forming pWP224. The T7 promoter TEV-PRgluc chimeric gene is then cloned as a partial *Xho*I fragment into the *Sal*I site of the binary vector SCV nos-nptII, forming pWP224-SCV, and transformed into plants and bred to homozygosity (plant B(PRgluc)).

25

Construction of a T7 promoter-TEV-Barnase chimeric gene.

The *Nco*I, *Sph*I PR-Gluc and CaMV polyadenylation sequences of pWP224 were replaced with the *Nco*I *Sph*I Barnase and CaMV polyadenylation sequences of pWP128 (Paul *et al*, *Plant Molecular Biology*, 19: 611-622 (1992)), forming pWP226. This chimeric T7 promoter-TEV-Barnase gene was cloned as an *Xho*I

fragment into the *SaII*-cut pSCB-nos-nptII, forming pWP226-SCV. The T7 promoter-TEV-Barnase gene could not be transferred intact into tobacco plants, indicating that, as observed previously in mammalian cells (Leiber *et al*, *Methods in Enzymology*, 217: 47-66 (1993)), the T7 promoter is recognised, albeit at low efficiency, by a eukaryotic RNA polymerase. Since Barnase is highly cytotoxic to all plant cell types (unlike Pr-gluc (Worrall *et al*, *The Plant Cell*, 4: 759-771 (1992)), any low level "constitutive" expression of Barnase would prevent regeneration of transformed plants. Mutations of the T7 promoter sequence can significantly reduce non-specific expression from the T7 promoter, whilst still allowing recognition by T7 RNA polymerase (Leiber *et al*, *Methods in Enzymology*, 217: 47-66 (1993)). Thus the T7 promoter of pWP226 is replaced with such a mutated promoter.

A mutated T7 primer:

5' GGGCTCGAGTTAATTCGACTCACTATACGG 3' (A *nXhoI* site added 5' to the T7 promoter)

and the M13 20' primer:

5' CGTTGTAAAACGACGGCCAG 3' (primes outside the polylinker of pTZ18)

are then used in a polymerase chain reaction to obtain a mutant T7 promoter TEV leader-Prgluc' fragment from pWP178-TEV, that is then cloned into pBluescript II KS- (Stratagene Ltd) as an *XhoI*, *HindIII* fragment forming pWP188-T7mut. The *KpnI*-*NcoI* fragment of pWP188-T7mut is then used to replace the *KpnI*-*NcoI* fragment of pWP226 forming pWP226-T7mut. The T7-mut promoter TEV-Barnase chimeric gene is then cloned as an *XhoI* fragment into the *SaII* site of the

binary vector SCV nos-nptII. forming pWP226-T7mut-SCV, and transformed into plants and bred to homozygosity (plant B (Barnase)).

In the progeny (plant AB(PRgluc) or plant AB(Barnase)), the T7RNP is present in the tapetum of these plants and promotes expression in the tapetum of either the T7-TEV-PRgluc or T7-mut-TEV-Barnase genes therefore causing male sterility. The use of the system in a hybrid seed production scheme is similar to the one described in Example 1 above.

EXAMPLE 4

T7 RNA Polymerase-Mediated Expression of GUS in Seeds

To demonstrate the utility of T7 RNA polymerase-mediated expression of proteins or RNAs in seeds or in the other parts of the hybrid plant, expression of GUS protein from such a system in seeds is described below.

Construction of a 35S CaMV promoter-modified T7 RNA polymerase chimeric gene.

For efficient use in eukaryotic cells, the phage T7-RNA polymerase protein (T7RNP) must be modified so that it is targeted to the cell nucleus. This has been achieved in mammalian (Leiber *et al*, *Nucleic Acids Research*, 17: 8485-8493 (1989)) and plant cells (Lassner *et al*, *Plant Molecular Biology*, 17: 229-234 (1991)) by the addition of a nuclear-targeting signal from the large T-antigen of SV40 to the N-terminus of the T7RNP. A similar SV40 leader -T7RNP gene fusion was constructed by Dr Andrzej Plucienniczyn in the following manner:

The T7RNP gene was isolated as an *Nru*I, *Bam*HI fragment from plasmid pGP1-2 (Tabor and Richardson, *Proc. Natl. Acad. Sci. USA*, 82: 1074-1078 (1985)) and

cloned between the *AccI* (rendered flush with Klenow) and *BamHI* sites of pUC19 forming the plasmid pT75. A leader sequence from the SV40 large T-antigen gene was then cloned in front of the *NruI* site of pT75, forming pT751.

5 The modified T7RNP gene of pT751 is then placed under control of a double 35S CaMV promoter. The *XbaI*-*BamHI* fragment containing the modified T7RNP gene is cloned between the *XbaI* and *BamHI* sites of pWP90, forming pWP179 (Figure 2A). pWP90 is identical to pWP91 (described in WO-A-9211379) except that the *KpnI*, *XbaI* A9 promoter fragment of pWP91 is replaced by a *KpnI*, *XbaI* double
10 35S promoter from pJIT 60 (described in WO-A-9211379). The 35S CaMV promoter-T7RNP chimeric gene is then cloned as an *SstI*, *XhoI* fragment into the *SstI*, *SalI* sites of pBin19. The resulting plasmid (pWP179-Bin) is then transformed into plants and bred to homozygosity (plant A).

15 ***Construction of a T7 promoter-TEV-GUS chimeric gene.***

An *EcoRI*, *EcoRV* fragment containing the Tobacco Etch Virus (TEV) leader sequence and the 5' region of β -Glucuronidase (GUS) from pRTL2GUS (Carrington and Freed, *Journal of Virology*, 64: 1590-1597 (1990)) is cloned between the *EcoRI*, *SmaI* sites of the vector pTZ18 (Pharmacia Ltd) forming
20 pGUS1 (cap-independent leader sequences such as TEV (Carrington and Freed, *Journal of Virology*, 64: 1590-1597 (1990)) have been shown to improve significantly the stability and translatability of RNA transcripts made by T7 RNA polymerase in plant protoplasts (Tuttle *et al*, 4th International Congress of Plant Molecular Biology, Abstracts p478 (1994)). A modified T7 primer:

25

5' GGGGCTCGAGTTAATACGACTCACTATAGGG 3' (An
XhoI site added 5' to the T7 promoter)

and the M13 20' primer:

5' CGTTGTAAAACGACGGCCAG 3' (primes outside the
polylinker of pTZ18)

5

are then used in a polymerase chain reaction to obtain a T7 promoter TEV leader-GUS' fragment that is cloned into pBluescript II KS- (Stratagene Ltd) as an *Xho*I, *Hind*III fragment forming pGUS2. The *Kpn*I-*Nco*I fragment of pGUS2 is then used to replace the *Kpn*I-*Nco*I A9 promoter of pWP91 (described in WO-A-9211379) forming pGUS3.

10

Primers:

5' CCGCATGCGATCCGGCTGCTAACAAAGCC 3' and
5' GGATATCAGATCTCGATCCGGATATAGTTCC 3'

15

are used in polymerase chain reaction with plasmid ET21a (Novagen) as template and the resulting T7 terminator sequence is cloned as a *Sph*I, *Eco*RV fragment between the *Sph*I and *Eco*RV sites of pGUS3 forming pGUS4. The *Nco*I, *Sph*I fragment from pRTL2GUS, containing the GUS and CaMV polyadenylation sequences, are then cloned between the *Nco*I and *Sph*I sites of pGUS4 forming pWP225. The T7 promoter TEV-GUS chimeric gene is then cloned as an *Xho*I fragment into the *Sa*I site of the binary vector SCV nos-nptII (pSCV-nos-nptII was made by cloning a nos promoter-nptII nos terminator chimeric gene between the *Eco*RV and *Eco*RI sites of pSCV1 (see Firek *et al*, *Plant Molecular Biology*, 22: 129-142 (1993) for information on pSCV1), forming pWP225-SCV, and transformed into plants and bred to homozygosity (plant B).

20

25

In the developing seeds resulting from a cross of plant A to B, T7RNP expression

results in the transcription of the T7-TEV-GUS gene and GUS protein accumulation in all cells and tissues where the 35S promoter is active. This demonstrates that expression of a heterozygous protein in a seed-specific manner can be obtained.

5

EXAMPLE 5

Activation of an AMS Gene by Specific Splicing

10 An AMS gene, such as A9-barnase or A3-glucanase, is built containing an artificial intron which prevents translation of the gene. An appropriate group I intron derived from a mitochondrial rRNA gene from *Neurospora crassa* is described in Guo *et al*, *The Journal of Biological Chemistry* 266 1809-1819 (1991). This intron is not able to self-splice and needs a specific protein helper for
15 splicing. In plants, the intron should not be spliced. Plant A (the first line) contains such an AMS gene, is fertile and bred to homozygosity. Plant B (the second line) contains an engineered gene encoding the protein needed for splicing: the CYT-18 protein from *Neurospora crassa*; the ORF is manipulated so that the protein will be targeted to the nucleus, and if necessary so that its other activity
20 (tyrosyl-tRNA synthetase) is abolished (Mohr *et al*, *Cell* 69 483-494 (1992)). This gene in itself has no effect on the plant containing it; plant B is fertile and bred to homozygosity. Cross between A and B is performed as described above and the seeds obtained give sterile plants. These can be used in a hybrid seed production scheme as described in Example 1 above. Other intron/helper protein pairs could
25 be used.

EXAMPLE 6**Activation of a Bicistronic AMS Gene by Protein VI of CaMV**

5 An AMS ORF (such as Barnase or PR glucanase as described above) is inserted in 3' of (after the Stop codon of) a first ORF (Zijlstra and Hohn, *The Plant Cell* 4 1471-1484 (1992); they describe the use of ORF VII from CaMV, but recommend the use of the ORF for NPTII, such that the AMS ORF is present on the same mRNA as the first ORF. Because only the first ORF is translated in
10 plant mRNA, the AMS ORF is not translated. The plant containing this bicistronic gene (plant A) is fertile and bred to homozygosity.

An activator of the translation of the AMS ORF in gene A is the product of ORF VI of CaMV, (Zijlstra and Hohn 1992, *ibid*). Gene B is built by placing ORF VI
15 of CaMV under control of an appropriate promoter such as A9. In plants (plant B), this gene has no effect and the plant is bred to homozygosity.

In plant AB resulting from the cross between A and B, the product of gene VI activates translation of the AMS ORF present on the bicistronic mRNA, and the
20 resulting protein causes sterility.

The system is then used as described in Example 1 above to generate a homogeneous population of male sterile plants, used to produce hybrid seeds.

EXAMPLE 7**Transcription Transactivation**

Gene A is an AMS gene under control of a specific promoter which is not active
30 in the absence of its cognate transacting factor.

Gene B is a gene coding for the transacting transcription activator, expressed in the appropriate tissue.

EXAMPLE 8

5

Ribozyme Inactivation of a Gene Necessary for Male Fertility

Dominant male sterility can be obtained by inhibiting expression of an endogenous gene needed for male fertility. This gene suppression can be done using antisense RNA technology or using ribozyme RNA technology. The latter can be deployed so that a binary system causing sterility can be designed and this is described below. The target gene to be suppressed can be identified for example by analysis of male sterile mutants. There are many examples of potential target genes (such as gene *ms2* of *Arabidopsis*, Aarts *et al.*, *Nature* 363 715-717 (1993)). Target genes from plants of interest can be cloned from other plants, using knowledge derived from the *Arabidopsis* gene or genes and using standard technologies (such as the use of heterologous probes, antibodies and PCR reactions using degenerate primers). A suitable target gene is called in this description "*ms*" and its gene product called "MS".

20

In plant A is introduced a T-DNA containing a ribozyme directed against a site (called site 1) in gene *ms*, and a mutated version of gene *ms* (called *ms1*-2*) where the ribozyme cleavage site has been mutated, and a different cleavage site created (site 2) without destroying the MS protein function. In this plant endogenous gene *ms* expression is destroyed by the ribozyme, but this is complemented by expression of gene *ms1*-2* which is resistant to ribozyme cleavage.

25

Plant A contains MS, and is therefore fertile, this fertility being conferred by the expression of *ms1*-2*, an allele of gene *ms*. It is bred to homozygosity.

Plant B expresses a ribozyme directed against site 2 of gene *msl*2*. This site is not present in gene *ms*, and therefore plant B has normal MS activity. It is fertile and bred to homozygosity.

5 Plant AB will lack MS activity because the ribozyme from plant A will inactivate gene *ms* and the ribozyme from plant B will inactivate gene *msl*2*. This plant will be sterile, and can be used to produce hybrid seeds as described in Example 1 above.

10 If restoration is needed, a new allele of gene *ms* (*msl*2**) can be made where site 2 would be mutated to be resistant to ribozyme cleavage, without destroying MS protein function.

15 For a given gene *ms*, such as *ms2*, characterised by the phenotype of a *ms* deficient mutant, and where sequence of the mRNA is known, the information needed to build the system is available.

20 As an example of this approach, a test system is the restoration of fertility of an *Arabidopsis thaliana* *ms2* male sterile line (Aarts *et al*, *Nature*, 363: 715-717 (1993)), using an *ms2* cDNA (C103) isolated from *Brassica napus* (Hodge *et al*, *The Plant Journal*, 2: 257-260 (1992)). The tapetum-specific A9 promoter can be used to drive expression of the *Brassica napus* *ms2* cDNA (C103). This construct will produce *ms2* protein in the tapetum and thereby restore fertility to plants in which the native *ms2* gene, RNA or protein has been disrupted.

Construction of a chimeric gene containing the tapetum-specific A9 promoter linked to the sense orientation of the C103 cDNA and transformation into ms2 Arabidopsis thaliana.

5 The anther-specific cDNA C103 was cloned into the *EcoRI* site of Lambda ZapII (Stratagene) by the addition of *EcoRI*/*NotI* linkers (Hodge *et al*, *The Plant Journal*, 2, 257-260 (1992)). The cDNA can be excised as a *NotI* fragment since there are no internal *NotI* sites. The cDNA is then cloned into *NotI*-cut pWP80 (UK Patent No 9028060.3) in the sense orientation. The chimeric gene is then excised from the pWP80 derivative with *XhoI* and is cloned into *SalI*-cut pBin19 (Bevan *et al*,
10 *Nucleic Acids Research*, 22, 8711-8721 (1984) (Figure 4)).

The pBin19 derivatives are transformed into the plant species of interest. Plants which are male sterile due to disruption of native ms2 gene function are male fertile upon transformation or crossing in of this restorer gene.

15 Since sequences of the *A. thaliana* and *B. napus* ms2 are not identical (89% identity between their coding regions, Figure 5), specific ribozymes can be designed that cleave only the *A. thaliana* or only the *B. napus* ms2 mRNA. these can be used in the binary system scheme as outlined previously.

20 EXAMPLE 9

Sterility Induction by Repressing the Inactivator of an Active AMS gene

25 In line A, the AMS gene is co-expressed with an inactivator of the AMS gene producing fertile plants. Line A is then crossed to Line B that expresses a repressor of the inactivator such that the hybrid AB is male-sterile.

An example of such a system is Barnase as the AMS gene, Barstar as the

inactivator and anti-Barstar as the repressor. Expression of Barstar from the tapetum-specific TA29 promoter restores fertility to sterile TA29-Barnase *Brassica napus* plants (Mariani *et al*, *Nature*, 357: 384-387 (1992)). Thus co-expression of Barnase and Barstar from the same tapetum-specific promoter, for example A3 or A9, will produce male-fertile plants. Barnase and Barstar expression can also be driven from different promoters providing that the temporal and spatial pattern of expression of Barnase is encompassed by the expression of Barstar. Thus the tapetum-specific promoters A3 and A9 which have similar patterns of expression (UK Patent Application No 9028060.3) can be used to drive Barnase and Barstar in the combinations A3-Barnase+A9-Barstar and A9-Barnase+A3-Barstar. Similar promoter combinations may be advantageous either to provide Barstar prior to Barnase expression in the cell or to produce more Barstar than Barnase in the cell.

A) Numbering and construction of genes

The active AMS gene: A3-Barnase (pWP131 (see UK Patent Application No 9028060.3))

The inactivator of the AMS gene combined with the AMS gene:

The inactivator gene is A9-Barstar: this was built by inserting the Barstar ORF as a BamHI-BglII fragment, produced by PCR from pWP127, in the BamHI site of p1415, in the sense orientation, yielding p3072. The SphI fragment from p3072 containing the A9-Barstar gene was inserted in the sphI site of pWP131 which contains the A3-Barnase-CaMV gene, yielding p2021. The salI-EcoRV fragment of p2021 which contains the 2 genes was then inserted in the SalI-SmaI sites of pBin 19 yielding p3118. This plasmid contains the 2 genes in the same T-DNA. It was introduced in AGL1 by electroporation.

The repressor gene of the inactivator:

The same Barstar ORF BamHI-BglII fragment, produced by PCR from pWP127 as described above, was inserted in the BamHI site of p1415 in the antisense orientation yielding p3073. The HindIII fragment of p3073 containing the A9-antiBarstar gene was inserted in the HindIII site of pBin19 yielding p3076. This plasmid was introduced in Agrobacterium by electroporation.

B) List of constructs introduced in plants and description

Genes are shown with their regulatory sequences (promoter and terminator); Genes are separated by "/".

p3118 A3-Barnase-CaMV/A9-Barstar-CaMV

p3076 A9-antiBarstar-CaMV

C) Description of plants

Transgenic plants were obtained and scored as in Example 1.

<u>Plasmid</u>	<u>Description of the plants</u>
----------------	----------------------------------

p3076:	14 plants obtained; 13 fertile; 1 sterile with abnormal flowers.
--------	--

D) Plant propagation, genetic analysis and crosses

As in Example 1, seeds from fertile transgenic plants (T0) are harvested (T1 seeds), planted and heterozygous and homozygous T1 plants can be identified by following the segregation of the marker gene in the T2 generation.

Homozygous plants from various primary transformants containing p3118 are crossed to homozygous plants from various transformants containing 3076. The hybrid seeds (F1) are planted and F1 plants are scored for fertility. When the 2 transgenes are efficient the F1 plants are sterile.

5

E) Conclusion

Given the known temporal and spatial activities of the A3 and the A9 promoter (Scott *et al*, *Plant Molecular Biology*, 17:195-207(1991)) plant A can be obtained. A gene able to reduce or suppress expression of the restorer gene has no effect on fertility. Plant B can be obtained.

10

EXAMPLE 10

fad2 mutants of *Arabidopsis thaliana* which are deficient in ER 18:1 desaturase are inhibited in germination at low temperatures (M F Miquel and J A Browse, *Plant Physiology*, 106: 421-427). This strongly suggests that driving seed specific antisense to this gene, giving rise to high oleic acid in the seed oil as described in WO 93/11245, would result in inhibition of seed germination of high oleate oilseed rape. Indeed, the authors conclude that the production of commercially viable high oleate (rape) oil "may not be possible". High oleic acid rape is a desired product for industrial feed stock.

15

20

Using the binary system as described above in Example 3 can alleviate this problem. Thus, lines A and B are created. The A line carries the phage T7 RNA polymerase protein (T7RNP) linked to a seed specific promoter such as the napin promoter. Any suitable promoter may be used, including a seed specific promoter which may be preferred over 35S since expression in the seed is higher. The B line carries the T7 promoter linked to the desaturase gene in the antisense orientation (this replaces GUS from Example 3). In the developing seeds resulting

25

from the cross A to B, T7RNP expression results in the transcription of the T7-TEV-antidesaturase gene. Both A and B can be multiplied separately without the gene being expressed. The A line is chosen to be or subsequently rendered male sterile (cytoplasmic male sterility is commonly used in the female parents of oilseed rape) or otherwise incapable of selfing, and the B line to be a suitable pollinator, thereby ensuring that seed collected on the hybrid carries the two components. There may be further refinements of the production system. (Note, however, that the ratio of A:B is certainly not 1:1, and may be around 95:5, thereby alleviating concerns about dilution of the AB seed. Alternatively, herbicide resistance may be added to the A line to allow elimination of contaminating B plants after pollination has taken place.) Only when the lines carrying the two components are crossed would expression of antisense ER18:1 desaturase occur.

In the developing seeds resulting from the cross A to B, T7RNP expression results in the transcription of the T7-antidesaturase gene. The desaturase enzyme level is thereby down regulated in tissues where the napin promoter is active, and seed resulting from the cross are high in oleic acid and thus suitable for industrial processing. Since these seeds are not intended for field planting, any gene expression during germination is no longer a problem. Seed from plants carrying the components can be germinated and therefore increased as normal.

As well as solving this particular problem, the binary system may be used in this way to express other enzymes involved in fatty acid synthesis, or in other processes occurring in the seed of crop plants, thereby ensuring security of production by having the target enzyme expressed only in the final product produced by the seed producer.

CLAIMS

1. A method for producing a plant having a desired phenotypic trait, the method comprising crossing a first line with a second line wherein each of the first and second lines lack the phenotypic trait in question and wherein at least one of the first and second lines is transgenic, and wherein when the desired phenotypic trait is male sterility, the male sterility does not result from the action of a transactivator polypeptide on a target nucleotide sequence.
2. A method as claimed in claim 1 wherein each of the first and second lines is transgenic.
3. A method as claimed in claim 2 wherein the first and second lines have the following characteristics:
- (a) the first line comprises homologous or heterologous DNA which controls the desired phenotypic trait and in the first line is adapted such that the line does not have the phenotypic trait, and
 - (b) the second line has DNA ("adapter DNA") which when present in the same plant as the phenotypic trait control DNA adapts the phenotypic trait control DNA to give rise to the phenotypic trait.
4. A method as claimed in any one of claims 1 to 3 wherein the phenotypic trait is male sterility.
5. A method as claimed in claim 3 or claim 4, wherein the phenotypic trait sequence in the first line comprises a sequence which, when expressed, confers the phenotypic trait on the plant, and wherein the adapter DNA of the second line acts to prevent (at least partially) expression of the phenotypic trait control sequence

in a hybrid.

6. A method as claimed in claim 4 or claim 5, wherein the first line comprises

5

(i) two genes, designated *ms* and *ms**, respectively, expression of at least one of which is needed for male fertility and

10

(ii) a prevention or disruption sequence (such as DNA encoding a ribozyme, designated R_{ms} , or DNA encoding antisense RNA, designated A_{ms} , specific for *ms*) which prevents or disrupts the proper expression of the *ms* gene; and

wherein the second line comprises:

15

(i) the two genes, designated *ms* and *ms**, respectively, expression of at least one of which is needed for male fertility and

20

(ii) a prevention or disruption sequence (such as DNA encoding a ribozyme, designated R_{ms*} , or DNA encoding antisense RNA, designated A_{ms*} , specific for *ms**) which prevents or disrupts the proper expression of the *ms** gene.

7. A method as claimed in claim 3 or claim 4, wherein the first line contains:

25

(i) an expressed gene giving rise to the phenotypic trait: and

(ii) an expressed restorer gene which restores the absence of the phenotypic trait: and

30

wherein the second line contains:

a repressor gene, which represses the activity of the restorer gene.

5 8. A method as claimed in claim 4 or claim 7, wherein: the expressed gene giving rise to artificial male sterility encodes the ribonuclease Barnase driven by a tapetum-specific promoter; the expressed restorer gene which restores male fertility is the Barstar toxin inhibitor; and the repressor gene is a gene encoding a ribozyme or antisense to the Barstar gene.

10

9. A method as claimed in claim 3 or claim 4, wherein the first line comprises an inactivated phenotypic trait gene, and the second line contains a gene which has the effect of activating the phenotypic trait gene.

15 10. A method as claimed in claim 9, wherein the first line contains a phenotypic trait gene coding for a protein, inactivated by one or more nonsense mutations, which may be the same as or different from each other, and wherein the second line contains a gene or genes coding for one or more suppressor tRNAs corresponding to the nonsense mutation(s).

20

11. A method as claimed in claim 4 or claim 10, wherein the first line expresses a mutated barnase gene driven by a tapetum-specific promoter, wherein the mutation in the barnase gene changes into an amber translational stop codon either the codon for isoleucine or the codon for tryptophan at position 4 or 35, respectively, of the mature barnase protein sequence; and wherein the second line expresses an amber suppressor tRNA which is capable of inserting, at an amber stop codon (UAG), either a leucine or a tryptophan into the nascent amino acid sequence.

25

30 12. A method as claimed in claim 9, wherein the first line comprises a

phenotypic trait gene under the control of a promoter or other regulatory sequence which cannot function for significant expression of the phenotypic trait gene in the first line; and wherein the second line comprises a gene which, when present in the same plant as the phenotypic trait gene with its associated regulatory sequence, allows that regulatory sequence to function sufficiently to cause significant expression of the phenotypic trait gene.

13. A method as claimed in claim 12, wherein the regulatory sequence in the first line comprises a promoter which does not function with endogenous plant RNA polymerase; and wherein the second line comprises a gene encoding an RNA polymerase which does function with the regulatory sequence in the first line.

14. A method as claimed in claim 13, wherein the promoter which does not function with endogenous plant RNA polymerase is the promoter from phage T7; and wherein the gene in the second line encoding an RNA polymerase is T7 polymerase.

15. A method as claimed in claim 14, wherein the phage T7-RNA polymerase is modified so that it is targeted to the cell nucleus.

16. A method as claimed in claim 9, wherein the first line contains a phenotypic trait gene which is driven by a promoter which is not active in the absence of its cognate *trans*-acting transcription factor; and wherein the second line comprises a tissue-specific gene encoding the *trans*-acting transcription factor.

17. A method as claimed in claim 9, wherein the first line contains a phenotypic trait gene interrupted by an inactivating sequence; and wherein the second line comprises a gene encoding an enzyme which is capable of splicing out the inactivating sequence.

18. A method as claimed in 17, wherein the inactivating sequence is an intron; and wherein the enzyme is a maturation enzyme.

19. A method as claimed in 18, wherein the intron is derived from yeast mitochondrial intron bI4 of the *Saccharomyces cerevisiae* cytochrome b gene; and wherein the enzyme is a yeast maturase.

20. A method as claimed in 18, wherein the intron is derived from the rRNA group I intron from *Neurospora crassa*; and wherein the enzyme is the protein CYT18.

21. A method as claimed in claim 2 wherein the phenotypic trait results from the non-expression of a gene normally carried by the plant.

22. A method as claimed in claim 21 wherein:

(i) the first line comprises an antisense sequence for the gene whose non-expression gives rise to the phenotypic trait, the antisense sequence being under the control of a promoter or other regulatory sequence which cannot function for significant expression of the antisense sequence; and

(ii) the second line comprises a gene which, when present in the same plant as the antisense sequence with its associated regulatory sequence, allows that regulatory sequence to function sufficiently to cause significant expression of the antisense sequence, such expression leading to down regulation of the gene whose non-expression gives rise to the phenotypic trait.

23. A method as claimed in claim 22 wherein the antisense sequence is under the control of the promoter from phage T7; and wherein the second line comprises

a gene encoding T7 RNA polymerase.

24. A method as claimed in any one of claims 21 to 23 wherein the gene whose non-expression gives rise to the phenotypic trait is one coding for a desaturase enzyme.

25. A method as claimed in any one of claims 1 to 3 wherein the phenotypic trait results in seed specific expression of one or more proteins.

26. A method as claimed in claim 25 wherein the protein is a pharmaceutically useful protein.

27. A method as claimed in claim 26 wherein the protein is a lymphokine, EPO, tPA, an interferon, a blood factor or an enzyme.

28. A plant obtainable by a method as defined in any one of the preceding claims.

29. A plant as claimed in claim 28 wherein the desired phenotypic trait is male sterility.

30. Propagating material of a plant as claimed in claim 28 or claim 29.

31. Propagating material as claimed in claim 30, which is seed.

32. A hybrid plant obtainable by crossing a male plant with a female, male-sterile plant as claimed in claim 29.


33. A plant which is useful as the first or second line as defined in any one or more of the preceding claims.

34. A method for producing a plant having a desired phenotypic trait, which comprises crossing a first line with a second line wherein each of the first and second lines lack the phenotypic trait in question and at least one of the first and second lines is transgenic.

5


35. A method as claimed in claim 34 modified by one or more of the features of claims 2 to 27.

1/9
FIG. 1A




2 / 9

FIG. 1B




3 / 9

FIG. 2A




4 / 9

FIG. 2B




5 / 9

FIG. 3



6 / 9



7/9
FIG. 5. I

```

1  .ATTCTGTTCTTGGTTTACTTAATCTTCTTTCTAGTTAAGTATATTCTTG  49
   |||
1  AATGGAATGGACAGTTTACTGTCTTAGTCTAAAAATGAACCTTTCTCTAT  50
   |||
50  TTGCTCATCACCAAAGCTTGTGATGGAGGCTCTCTTCTTGAGTTCTTCTT  99
   |||
51  TTCTTATT..TCTTAGTTTGTGATGGAAGCTCTCTTCTTGAGTTCTTCTT  98
   |||
100 CTTCTCCATTGTAGGGTCAAACAAGCTTACTAGGTTACACAACCATTGT  149
   |||
99  CCTCTCCATTGCTGCTTCAATCAAGCTTTCAGATTACACGACCGTCGT  148
   |||
150 GTCTGGTCTACAGTGATTAGAGATAAGAAAAGGTTCCGGTCCCACTTGGTG  199
   |||
149 GACTGGTGCACTTTGTTAAGGGACAAGAAAAGGGTAGGACCCACCTGGTG  198
   |||
200 CCGTGTAGGTGGTGGTGGTGGTGGTGGGAGAAACAGTAACGCAGAGAGTC  249
   |||
199 CCGCGTAGGTGGTGGTGGCGGTGATGGGAGAAACATCAAACCAGAGAGGC  248
   |||
250 CTATTCGGGTTTCTTCGCTTTTGAAGACAGAGGTCAGGTAAGTACTGATTAGG  299
   |||
249 CTATTAGGGTCTCATCGCTTTTGAAGACAGAGGTCAAGTATTGATTAGG  298
   |||
300 GAACAGAGTTCGCCGGCTATGGATGCTGAGACATTGGTTCTGTCTCCAAA  349
   |||
299 GAACAGAGTTCGCCTGCTATGGACGCTGAGACATTGGTTCTGTACACCTAA  348
   |||
350 CGGGAATGGGAGAACCATTGAGATCAATGGAGTAAAGACTTTGATGCCTT  399
   |||
349 TGTGAATGGTACAGCCATTGAGATGAATGGAGTGAAAACCTCTGATGCCTT  398
   |||
400 TTAGTGGCGCTTCTATGGTGGGGATGAAAGAAGGACTTGGCATAATCAGT  449
   |||
399 TCAATGGTGCTGATATGGTGGGGATCAAACAAGGACTTGGCATCGTTAGT  448
   |||
450 TTCCTCCAAGGGAAGAAGTTTCTAATCACTGGCTCGACCGTTTCTTAGC  499
   |||
449 TATCTACAAGGGAAGACGTTTCTAATCACTGGCTCCACTGGCTTCTTAGC  498
   |||
500 TAAAGTACTGATTGAGAAAGTCTTGAGAATGGCTCCTGATGTCAGCAAGA  549
   |||
499 TAAAGTACTGATTGAGAAGGTCTTGAGAATGGCTCCTGATGTTGGGAAAA  548
   |||
550 TATATCTCTTGATTAAAGCCAAAAGCAAAGAAGCTGCGATCGAGCGGCTA  599
   |||
549 TATATCTCTTGATTAAAGCTAAAAACAAAGAAGCAGCGATCCAGCGGTTA  598
   |||
600 AAGAACGAGGTGTTAGATGCAGAGCTTTTAAATACTCTAAAAGAGACTCA  649
   |||
599 AAGAACGAGGTGTTAGATGCAGAGCTTTTAAAAATCTAAGAGAGACTCA  648
   |||
650 TGGAGCATCTTACATGTCTTTCATGTAACTAACTCATCCCTGTGACCG  699
   |||
649 TGGAGCATCTTTCATGTCTTTCATGTAGACAAGCTTGTCCCTGTGACAG  698

```

8 / 9
FIG. 5. II

700 GAAACATTTGCGATTCAAACATTGGGTTGCAAGCAGATTCAGCTGAAGAG 749
|||||
699 GAAACATTTGCGATTCAAACATTGGGTTGCAACAGATTCAGCAGAGGAG 748
|||||
750 ATTGCGAAAGAAGTTGATGTTATAATCAATTCTGCTGCTAATAACAACCTT 799
|||||
749 ATTGCAAAAGAAGTTGATGTGATTATCAACTCAGCTGCCAATAACAACCTT 798
|||||
800 CAATGAAAGATACGATGTTGCTCTGGACATCAACACAAGAGGGCCCGGTA 849
|||||
799 CAATGAAAGATATGATGTTGCTTTGGACATAAACACACGAGGGCCTGGTA 848
|||||
850 ATCTCATGGGATTCGCCAAGAAGTGCAAGAAACTCAAACCTGTTCTTGCAA 899
|||||
849 ATCTCATGGGATTCGCCAAGAAGTGCAAGAAACTCAAGCTTTTCTTGCAA 898
|||||
900 GTATCCACAGCTTATGTGAATGGACAAAGACAAGGAAGGATCATGGAGAA 949
|||||
899 GTATCTACAGCTTATGTGAACGGACAAAGACAAGGAAGGATCATGGAGAA 948
|||||
950 GCCATTTTCTATGGGAGATTGTATAGCAACAGAGAACTTCCTCGAAGGAA 999
|||||
949 GCCCTTCTCGATGGGAGATTGTATAGCTACAGAGAACTTCATGGAAGGTA 998
|||||
1000 ACAGAAAAGCATTAGATGTTGATAGAGAGATGAAGTTAGCTCTTGAAGCT 1049
|||||
999 ACAGGAAAGCATTAGATATCGATAAAGAGATGAAGCTAGCTCTTGATGCT 1048
|||||
1050 GCTAGAAAAGGGACTCAAAATCAAGATGAGGCACAGAAGATGAAGGATCT 1099
|||||
1049 GCAAGAAAAGGGACTCAAGATCAAGATGAGGCGCAGAAGATGAAGGATCT 1098
|||||
1100 CGGTCTAGAGCGGGCAAGATCATATGGATGGCAAGACACTTATGTTTTCA 1149
|||||
1099 CGGTCTAGAGAGGGCAAGATCATATGGATGGCAAGACACTTATGTTTTCA 1148
|||||
1150 CCAAAGCAATGGGTGAGATGATGATCAATAGCACTCGAGGAGACGTACCT 1199
|||||
1149 CCAAAGCAATGGGAGAAATGATGATCAATAGCACTAGAGGGGACGTACCT 1198
|||||
1200 GTTGTTATTATAAGGCCTAGCGTCATCGAAAGCACTTACAAAGATCCTTT 1249
|||||
1199 GTGGTTATTATAAGGCCTAGCGTCATCGAAAGCACTTACAAAGACCCTTT 1248
|||||
1250 CCCTGGATGGATGGAAGGAAACAGGATGATGGATCCTATAGTTTTATGTT 1299
|||||
1249 CCCTGGATGGATGGAAGGAAACAGGATGATGGATCCTATAGTGCTGTGTT 1298
|||||
1300 ACGGGAAGGGGCAACTCACGGGGTTTTTGGTTGATCCAAAAGGAGTTCTT 1349
|||||
1299 ATGGAAAAGGACAGCTCACAGGGTTCTTGGTTGATCCAAAAGGAGTTCTT 1348
|||||
1350 GATGTAGTTCCTGCTGATATGGTTGTTAATGCAACGTTAGCTGCTATAGC 1399
|||||
1349 GATGTGGTTCCGGCTGATATGGTCGTTAATGCGACATTAGCTGCTATAGC 1398
|||||

9 / 9
FIG. 5. III

```

1400 AAAGCATGGAATGGCAATGTCAGATCCGGAACCTGAAATAAACGTGTATC 1449
      |||||
1399 AAAGCATGGAATGGCTAAGGCAGATACAGAACCTGAGATAAACGTGTATC 1448
      |||||
1450 AGATCGCTTCTTCGGCGATAAACCCGCTGGTTTTTCGAAGACTTAGCGGAG 1499
      |||||
1449 AGATCGCTTCTTCAGCGATAAATCCTCTTGTTTTTCGAGGACTTAGCTGAG 1498
      |||||
1500 CTTCTTTATAAACCCTACAAAACATCCCCATGCATGGACTCTAAAGGTGA 1549
      |||||
1499 CTTCTTTATAAACCATTACAAATCTACCCCGTGCATGGACTCGAAAGGTGT 1548
      |||||
1550 TCCTATTATGGTGCGTTTGATGAAACTTTTCAATTCCGTTGATGATTTCT 1599
      |||||
1549 TCCTATTAGGGTGCCTTTGATGAAGCTTTTCGACTCCGTTGATGATTTCT 1598
      |||||
1600 CGGATCATTTGTGGAGAGATGCTCAAGAACGGAGTGGGTTGATGAGTGGT 1649
      |||||
1599 CGGATCATTTGTGGAGAGATGCTCAAGAACGGAGTGGATTAATGAATGGT 1648
      |||||
1650 ATGAGTTCAGCGGATAGTAAGATGATGCAGAAGCTAAAGTTTATATGCAA 1699
      |||||
1649 ATGGACTCATCGGATAGTAAGATACTACAGAAGCTTAAATTCATTTGCAA 1698
      |||||
1700 GAAATCTGTTGAACAAGCCAAACACCTTGCTACTATTTATGAGCCATACA 1749
      |||||
1699 GAAATCTATTGAGCAAGCCAAACACCTTGCCACTATTTATGAGCCATACA 1748
      |||||
1750 CTTTCTATGGTGGAAGATTTGATAACAGCAATACACAGAGATTAATGGAG 1799
      |||||
1749 CTTTCTATGGTGGAAGATTTGATAACAGCAATACACATAGATTAATGGAG 1798
      |||||
1800 AATATGTCAGAGGACGAGAAGAGAGAATTTGGATTTGATGTTGGAAGCAT 1849
      |||||
1799 AATATGTCTGAAGAAGAGAAGCTTGAGTTTGGGTTTGATGTTGGAAGCAT 1848
      |||||
1850 TAACTGGACGGACTACATTACAAACGTTACATTCCCGGTTTAAGAAGGC 1899
      |||||
1849 TAACTGGAATGACTACATTACAAATGTTACATTCCCGGTTTAAGAAGAC 1898
      |||||
1900 ATGTCTTGAAAGGAAGAGCTTTA 1922      ms2
      |||||
1899 ATGTTTTGAAAGGAAGGGCTTAG 1921      C103

```

Nucleotide identity

Leader plus coding 87.5%

Coding only 89 %

Leader only 44.5 %

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 95/00188

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/82 A01H5/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 412 911 (PLANT GENETIC SYSTEMS NV) 13 February 1991 see the whole document ---	1-3
X	WO,A,92 01799 (PALADIN HYBRIDS INC) 6 February 1992 cited in the application see the whole document ----	1-4
X	SCIENCE, vol. 258, 11 December 1992 LANCASTER, PA US, pages 1773-1775, LLOYD, A.M., ET AL. 'Arabidopsis and Nicotiana anthocyanin production activated by maize regulators R and C1' see the whole document ----- -/--	1-3



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 April 1995

Date of mailing of the international search report

19.05.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Maddox, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 95/00188

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	THE PLANT CELL, vol. 4, May 1992 pages 583-595, SWINBURNE, J., ET AL. 'Elevated levels of activator transposase mRNA are associated with high frequencies of dissociation excision in Arabidopsis ' see the whole document ----	9
X	WO,A,91 09957 (DU PONT) 11 July 1991 see examples 12,13 ----	1-3,9, 17,25, 28,30, 31,33-35
X	EP,A,0 573 767 (NIHON NOHYAKU CO LTD) 15 December 1993 see the whole document ----	1-3,12, 13
X	AU,A,7 195 191 (NIHON NOOHYAKU) 12 March 1992 see page 55 - page 56 ----	1-3,12, 13
X	EP,A,0 412 006 (PLANT GENETIC SYSTEMS) 6 February 1991 see page 6, line 9 - line 24 see page 8, line 10 - line 22 ----	1-3,12, 13,21,22
X	PLANT MOLECULAR BIOLOGY, vol. 17, 1991 pages 229-234, LASSNER, M.W., ET AL. 'Targeting of T7 RNA polymerase to tobacco nuclei mediated by an SV40 nuclear location signal' see page 233, last paragraph ----	33
P,X	EP,A,0 589 841 (CIBA GEIGY AG) 30 March 1994 cited in the application see the whole document ----	9,16, 32-34
P,X	WO,A,94 29465 (NUNHEMS ZADEN B V ;DIRKS ROBERT (BE); TRINKS KLAUS (DE); UIJTEWAAL) 22 December 1994 see page 15 ----	1-3
P,X	WO,A,94 19477 (CALGENE) 1 September 1994 see the whole document ----	33
A	EP,A,0 425 004 (AVEVE NV ;CLOVIS MATTON N V (BE); SOLVAY (BE)) 2 May 1991 see page 5, line 37 - line 48 ----	1-35
	-/--	

INTERNATIONAL SEARCH REPORT

Intern. Appl. No.
PCT/GB 95/00188

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A,4 990 607 (KATAGIRI FUMIAKI ET AL) 5 February 1991 see column 2, line 60 - line 65 ----	16
A	WO,A,91 13994 (CSIRO) 19 September 1991 see page 5, line 16 see page 10, line 16 - line 31 ----	1-4
A	THE EMBO JOURNAL, vol. 10, 1991 pages 1793-1802, OEDA, K., ET AL. 'A tobacco bZip transcription activator (TAF-1) binds to a G-box-like motif conserved in plant genes' see page 1799, left column -----	16

INTERNATIONAL SEARCH REPORT

information on patent family members

Inter. Appl. Application No

PCT/GB 95/00188

Patent document and search report	Publication date	Patent family member(s)	Publication date
EP-A-0412911	13-02-91	AU-B- 625509 AU-A- 6068890 WO-A- 9102069 JP-T- 3503004	16-07-92 11-03-91 21-02-91 11-07-91
WO-A-9201799	06-02-92	AU-B- 648322 AU-A- 8098391 CA-A- 2087703 EP-A- 0540561 JP-T- 6501380	21-04-94 18-02-92 21-01-92 12-05-93 17-02-94
WO-A-9109957	11-07-91	AU-B- 639059 AU-A- 6974791 EP-A- 0506763	15-07-93 24-07-91 07-10-92
EP-A-0573767	15-12-93	AU-B- 3824893 JP-A- 6046874	04-11-93 22-02-94
AU-A-7195191		NONE	
EP-A-412006	06-02-91	AU-A- 6273390 WO-A- 9102068	11-03-91 21-02-91
EP-A-0589841	30-03-94	BR-A- 9303877 CA-A- 2106718	29-03-94 25-03-94
WO-A-9429465	22-12-94	EP-A- 0628635 AU-B- 6972394	14-12-94 03-01-95
WO-A-9419477	01-09-94	NONE	
EP-A-0425004	02-05-91	NL-A- 8902452 NL-A- 9001711 CA-A- 2026703 JP-A- 3280883	01-05-91 01-05-91 04-04-91 11-12-91
US-A-4990607	05-02-91	US-A- 5223419	29-06-93
WO-A-9113994	19-09-91	NONE	